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Medication adherence in individuals taking multiple medications has received 
little research attention, despite its importance in clinical treatment and its relevance to 
achieving optimal health outcomes. With the growth of the aging population and 
prevalence of chronic diseases, adherence to multiple medication regimens has become a 
critical issue. This project, consisting of three related studies, investigated medication 
adherence of cancer patients who received an allogeneic hematopoietic cell transplant 
(alloHCT) and whose conditions require adherence to complex, multiple medication 
regimens for prolonged periods of time.  
The Information-Motivation-Behavioral Skills (IMB) model was the theoretical 
framework for the study. This model posits that well-informed, highly motivated 
individuals have better adherence behaviors. In addition to having optimal information 
and motivation, patients also need to develop the appropriate behavioral skills to 
	maximize the value of information, motivation and aid adherence. Thus, within this 
framework, the link between information, motivation, and adherence is mediated by 
behavioral skills. Using the IMB model, the aim of this project was to examine different 
approaches to facilitating medication adherence after transplant. The first study used a 
mixed-methods approach to examine the feasibility of using an electronic pillbox for 
assessing adherence to multiple medications. The second study utilized patient interview 
data to assess the link between social support and adherence to multiple medications. The 
third study also used patient interview data to identify adherence determinants and 
strategies that patients used after transplant.  
The results of the first study show that even though some features of the 
electronic pillbox need to be modified, it is feasible to use it to facilitate medication 
adherence for patients after transplant. The second study demonstrated the importance of 
social support from lay caregivers, such as spouse and family members, as well as 
healthcare providers, for adherence tasks after transplant. Lay caregivers provided 
emotional and practical support, whereas healthcare providers were the main source of 
informational and medical support. The third study identified various determinants that 
facilitated and hindered medication adherence. The study also suggests practical lessons 
for adherence to multiple medications. Collectively, the findings provide a foundation for 
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Medication adherence—taking medications in prescribed amounts and intervals—
is important for any individual undergoing medical treatment. Despite the importance of 
taking medications, patients face challenges adhering, and about half of patients with 
chronic health conditions do not, resulting in poor health outcomes and greater healthcare 
costs (Bosworth et al., 2011; Brown & Bussell, 2011; Sabaté, 2003). It is found that 
adherence is especially challenging for patients with chronic diseases; though these 
patients have to persistently maintain adherence behavior, their rate of adherence drops 
dramatically after the first six months of treatment (Osterberg & Blaschke, 2005). 
Moreover, adherence is especially challenging for patients with multiple medications; 
studies show that adherence decreases as the number of pills taken increases (Claxton, 
Cramer, & Pierce, 2001; Pantuzza, Ceccato, Silveira, Junqueira, & Reis, 2017). Since 
taking multiple medications (more than five) has become more prevalent (Kantor, Rehm, 
Haas, Chan, & Giovannucci, 2015), it is all the more important to study adherence to 
multiple medications.  
Patients who undergo allogeneic hematopoietic cell transplant (alloHCT) typically 
must take multiple medications over extended periods of time. Medication adherence is 
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critical for this population, since most potential health risks after transplant, including 
morbidity, mortality, hospital readmissions, and healthcare costs, can be prevented with 
proper adherence (Bishop, Rodrigue, & Wingard, 2002; Hoodin, Harper, & Posluszny, 
2010). However, due to the complexity of their medication regimens (that often involve 
dozens of medications) and the extended period of the treatment (especially critical for 
the first 100 days after hospital discharge), medication adherence is challenging for 
patients after alloHCT (Tomblyn et al., 2009). Adherence to medication in this patient 
population is understudied; a recent review of literature, which only covered five studies, 
found that the rate of adherence for cancer patients with hematopoietic stem cell 
transplant ranged from 33% to 95% and suggested the need for further research in this 
area (Morrison, Martsolf, Wehrkamp, Tehan, & Pai, 2017). Another study, examining 
task distribution between patient and caregiver, found that adherence varies between 19% 
to 100% depending on the task and who is responsible for completing it, indicating that 
there is significant variation and complexity in adherence tasks (Posluszny et al., 2018). 
Therefore, the dissertation research seeks to examine adherence of patients after alloHCT, 
who need to adhere to multiple medication regimens. The first study seeks to examine the 
feasibility of using an electronic pillbox for patients after alloHCT to manage and 
maintain adherence for multiple medications. The second study explores the sources and 
the role of social support in this sample. Finally, the third study investigates the 




Despite the importance of adherence to multiple medications required by some 
patient populations, it is understudied and remains a challenge. In order to better 
understand and examine ways to improve adherence to multiple medications for leukemia 
and lymphoma patients after alloHCT, the following questions were addressed in this 
study: What is the feasibility of using digital technology for multiple medication 
regimens, what is the role of social support, and what are the psychosocial determinants 
and strategies of medication adherence for leukemia and lymphoma patients after 
receiving allogeneic hematopoietic cell transplant (alloHCT)?  
Purpose of the Study 
The purpose of this study was to provide a better understanding of adherence to 
multiple medications for patients with leukemia and lymphoma who received allogeneic 
hematopoietic cell transplant (alloHCT), and examine factors that are critical for the 
optimization of medication adherence for their survival.  
Specific Aims 
The specific aims of this study were to: 
1. Conduct an observational study, which will identify the feasibility of using an 
electronic pillbox, as well as its benefits and limitations.  
2. Examine the sources and the role of social support for adherence and the care 
of patients after transplant.  




This study is based on the Information-Motivation-Behavioral Skills (IMB) model 
(see Figure 1.1), which is a comprehensive and validated health behavior change 
framework initially developed for patients undergoing highly active antiretroviral therapy 
(also known as HAART) (Fisher, Fisher, Amico, & Harman, 2006). According to the 
IMB model, information, motivation, and behavioral skills relevant to adherence are 
needed for optimal medication adherence. The adherence information and motivation can 
be demonstrated through behavioral skills and can influence adherence behavior and, 
eventually, health outcomes. 
Although the IMB model was first designed for preventive health behavior 
changes in individuals with HIV, its concepts and framework can also be applied to 
patients with different chronic conditions requiring complex medications, such as 
diabetes (Mayberry & Osborn, 2014; Osborn & Egede, 2010). Thus, this model also 
seems to be suitable for explaining medication adherence for patients after alloHCT. 
Given that the some of the patients after alloHCT have to take at least 24 medications at 
different scheduled times every day, access to accurate information, positive motivation, 
and effective behavioral skills are critical predictors of medication intake. Having 
accurate information about the medication dosage, schedule, and side effects would 
provide patients with a sense of urgency and help them make more health-conscious 
decisions. Motivation, which includes having a positive attitude and beliefs and receiving 
social support,1 would help them stay positive and maintain adherence behavior. Relevant 
                                               
1 Social support is an especially strong predictor of medication adherence. Previous studies have shown a 




skills to manage and maintain medication adherence are needed in order to leverage 
adequate information and motivation in improving adherence.  
 Each of the three studies that comprise this dissertation focuses on different 
constructs in the IMB model. Study 1 examines ways to optimize adherence behavior as 
measured by an electronic monitoring system called the MedMinder (Maya, 
Massachusetts, USA). According to the IMB model, medication adherence, which is 
influenced by the three components (Information, Motivation, and Behavioral skills), can 
be measured by optimal adherence (an arbitrary threshold), proper dosing (taking the 
correct pills), and adherence levels over time (Fisher et al., 2006). Other studies have 
found that the use of an electronic pillbox provides the most objective measure of 
adherence, and that it also enhances adherence behavior (McGillicuddy et al., 2015; 
Ruddy, Mayer, & Partridge, 2009). Bringing these together, Study 1 examines adherence 
by observing the use of an electronic pillbox, which can help patients maintain optimal 
levels of adherence over time. We predict that a sizable subgroup of patients will be able 
to use the pillbox, and we will describe how many patients are willing to use the pillbox 
and how frequently and accurately they make use of an electronic pillbox.  
Study 2 focuses on social motivation in the motivation component of the IMB 
model, which concerns perceptions of social support from others (Fisher et al., 2006). We 
predict that social support plays a significant role for individuals with multiple 
medications and that different types of support matter. We will describe the sources of 
support and the types of support received at length.  
Finally, Study 3 examines each of the constructs in the IMB model to identify the 
determinants of and strategies for medication adherence. We will thus describe the 
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determinants and strategies of medication adherence that patients developed and used, 
which could be also useful for other individuals in malignant health conditions prescribed 
with multiple medications. 
 
 
Figure 1.1. The Information-Motivation-Behavioral Skills (IMB) Model. Adherence 
Information, Motivation and Behavioral Skills determine the level of Medication 
Adherence and Health Outcomes. Information and Motivation also influence Behavioral 
Skills, which in turn influence Medication Adherence and Health Outcomes (Fisher et al., 
2006)  
Significance of the Study 
Adherence to medication remains a significant challenge in the treatment and 
management of chronic diseases and is especially problematic for patients who must take 
multiple medications (Allegrante, Wells, & Peterson, 2019; Bosworth, 2010). Two 
secular trends have made this challenge even more salient for healthcare: 1) life 
expectancy has increased, and 2) more people with chronic conditions are now prescribed 
multiple medications (Cross, Elliott, & George, 2016; Kantor et al., 2015; Patton et al., 
2017). Moreover, medication adherence of patients who receive alloHCT is understudied 
despite its widespread adoption among more than 8,000 patients who receive alloHCT in 
Adherence information
- About what do and when to do it
- About side effects and drug interaction
- About heuristics and implicit theories 
regarding adherence
Behavioral skills for acquiring, self-cueing, and 




- Personal motivation: attitude, outcome 
expectancies, outcome beliefs
- Social motivation: Social support/lay care 
partner available
Medication adherence 
Daily adherence: Regimen dose and 
timing (% of prescribed doses missed 
per morning, noon, afternoon, evening)
Self-reported correct medication intake
Plasma level of immunosuppressants
Health outcomes
- Complications





the United States alone for cancer treatment, and the number continues to increase 
(D’Souza, Pasquini, & Zhu, 2016). While the survival rate of patients after alloHCT has 
improved over time with technological and other treatment advances, patients are still 
exposed to high risks of late complications, including the graft-versus-host disease 
(GVHD) that can result in death. Thus, a deeper understanding of the transplant survivors 
is needed (Gooley et al., 2010; Hashmi, Carpenter, Khera, Tichelli, & Savani, 2015; 
Majhail et al., 2013). Adherence to their prescribed medications can help reduce the risks 
of potential complications and side effects, but the regimen becomes increasingly 
complex with multiple medications, usually managing at least 18 medications with 24 
different types of pills (Tomblyn et al., 2009). Thus, a study of this particular patient 
population may offer useful insights into multiple medications adherence. 
Definition of Terms 
Allogeneic Hematopoietic Cell Transplant (alloHCT): A type of cell transplant, 
which is commonly used for patients with leukemia and lymphoma cancer, where the 
person receives new and healthy blood-forming stem cells from a donor, who is 
genetically non-identical, but very similar, such as brothers and sisters (American Cancer 
Society, 2017). There are higher chances of psychological distress, physical side effects 
and complication, such as graft-versus-host disease, and other infections after the 
transplant since the patient is receiving blood-forming stem cells from a foreign donor 
(Foster et al., 2005; Hoodin et al., 2010). 
Medication Adherence: The extent to which patients follow provider 
recommendations about day-to-day treatment with respect to the timing, dosage, and 
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frequency (Bosworth et al., 2011). According to the IMB model, medication adherence is 
influenced by the information, motivation, and behavioral skills that are relevant to 
adherence, and it can be measured by optimal adherence (95% or above), proper dosing 
(taking the correct pills), and adherence levels over time (Fisher et al., 2006). 
MedMinder (Maya, Massachusetts, USA): Similar to the functions of 
microelectronic monitoring systems (MEMS), the MedMinder is also an electronic 
medication pillbox, which transmits real-time data of pillbox activities (in hour, minute 
and seconds), including cap opening times and date, directly to the MedMinder central 
system using cellular signals. Patients, caregivers, and healthcare providers can monitor 
the medication adherence activities. This is the more suitable device for patients with 
multiple medications because one MedMinder pillbox carries 28 separate compartments 
that are divided into four different times of a day (morning, afternoon, evening, and night) 
for seven days (Monday to Sunday). It has functions of sending notifications and alarms 
at the appropriate times of dosage.  
Delimitations 
The delimitations of the study included: 
1. The data were solely collected at a hospital in an urban area and it was a small 
sample study. Therefore, it is not certain how generalizable the findings are to the 
overall population.  
2. About half of the leukemia and lymphoma patients at the hospital came from a 
minority background, but only English and Spanish speaking participants are 
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included in the study. There is a possibility that some were excluded from the 
study due to language difficulties.  
Use of Human Subjects and Ethical Considerations 
All study materials and protocols were approved by the respective Institutional 
Review Board (IRB) at the institutions related to the study, including Teachers College, 
Columbia University. Relevant information regarding the study was shared with 
participants, and they were asked to sign a written informed consent prior to participation. 
Electronic data were stored in a secured computer with a passcode, and the other 
documented data were placed into individual research participant folders, which are 
stored in a locked file cabinet in the office of the study institution. Only study personnel 
had the access to the stored files (both paper and electronic). All folders and data used for 
data analysis for individual participants were identified with unique patient numbers. No 
personal identification information was or will be published or disclosed to third parties 
without prior written consent of the participant. Patients were informed that they could 
skip questions and that they could also withdraw from the study at any time.  
The dissertation project presented no potential risks or harms or co-interventions 
for the participants; however, in cases of unexpected emergency, study staff were 
available throughout the study period to respond accordingly. Participation in the study 
was thought to benefit patient participants in several ways: facilitating easier intake of 
medications on time; becoming more knowledgeable and informed about the importance 
of medication adherence; and becoming more motivated to make changes in their 
adherence behavior.  
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Organization of the Dissertation 
This chapter has provided an overview of the study and its significance in the 
effort to better understand adherence to multiple medications in patients who have 
undergone alloHCT. The next three chapters (Chapter II, III, and IV) will present the 
three different studies that comprise the dissertation. The first study (Chapter II) will 
examine the feasibility of using electronic monitoring systems for multiple and complex 
medication regimens. The second study (Chapter III) investigates the sources and the role 
of social support. And the third paper contained in Chapter IV examines the determinants 
and practical strategies of medication adherence that patients used. Finally, Chapter V 
concludes with a general discussion of the overall contribution these studies make to 
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ELECTRONIC MONITORING OF ADHERENCE TO MULTIPLE MEDICATIONS: 
PROMISES AND CHALLENGES 
Abstract 
Background: An electronic pillbox can serve as a tracking device for adherence to a 
complex medication regimen. Blood cancer patients receiving an allogeneic 
hematopoietic cell transplant (alloHCT), typically prescribed with multiple pills, can 
benefit from it. Their medication adherence plays a critical role in post-transplant 
survival, as it can help limit severe side effects and toxic drug interactions. However, 
existing studies report a wide range of adherence rates. 
Objective: The objective of this mixed-methods study was to test the feasibility of using 
an electronic pillbox for tracking a multiple-medication regimen in the first 180 days at 
home following an alloHCT.  
Methods: Patients after alloHCT (n = 33, 45.5% female, age: M = 54.18, 45.5% ethnic 
minority) received an electronic pillbox. Most patients (n = 28, 84.8%) used the pillbox 
for up to 180 days after the hospital discharge and their signal transmission rate was 
calculated. Data were lost for one patient, so total adherence was calculated for 27 
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individuals (81.8%). Patients (n = 28) were also interviewed about their experiences 
using the electronic pillbox.  
Results: Most patients used their pillbox immediately after their discharge and continued 
using it beyond 180 days. The average adherence score was 55%, and there was large 
variability in signal transmission rates. Based on the interviews, patients reported ease of 
use and benefits of the electronic pillbox, but they also reported challenges, such as the 
size of the box and limited battery life. The paper discusses the promise associated with 
medication monitoring using an electronic pillbox.  
Conclusion: It is feasible to use an electronic pillbox for patients taking multiple 
medications. Overall, patients had a positive experience using an electronic pillbox. 
However, a more user-friendly device would have great potential for real-time 
interventions to facilitate adherence to multiple medication regimens.  
 
Keywords: allogeneic hematopoietic cell transplant; cancer; electronic medication 




Adherence to multiple medications is an increasingly important issue for patient 
care due to aging populations and the higher prevalence of chronic conditions and 
multimorbidity (Buttorff, Ruder, & Bauman, 2017; Sabaté, 2003; van Oostrom et al., 
2016; Wu & Green, 2000). A majority of adults in the US (59%) take at least one 
prescription medication, and 15% take five or more (Kantor, Rehm, Haas, Chan, & 
Giovannucci, 2015). However, adherence is problematic; patients take only to half of the 
medications as prescribed, and the rate of adherence for patients with chronic conditions 
varies (Costa et al., 2015; Osterberg & Blaschke, 2005; Sabaté, 2003). As a meta-analysis 
of 95 clinical trials found, 40% of the patients stopped taking the medication under study, 
undermining the validity of the trial results (Blaschke, Osterberg, Vrijens, & Urquhart, 
2012).  
Taking multiple medications remains an understudied challenge (Inauen et al., 
2017; Pasina et al., 2014). The complexity of the medication regimen (as measured by the 
number of different medications taken daily and/or the number of doses per day) was 
associated with decreased adherence in several reviews (Costa et al., 2015; Ingersoll & 
Cohen, 2008; McDonald, Garg, & Haynes, 2002; Richter, Anton, Koch, & Dennett, 
2003), including in patients with blood cancer (Hall et al., 2016). Patients with blood 
cancer receiving an allogeneic hematopoietic cell transplant (alloHCT) are a good test 
case for studying multiple medication intake. They are routinely prescribed at least 24 
pills per day when they are discharged from the hospital (Freifeld et al., 2011; Neumann, 
Krause, Maschmeyer, Schiel, & von Lilienfeld-Toal, 2013; Tomblyn et al., 2009). 
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Medications must be taken at carefully timed intervals to avoid toxic drug interactions. 
Furthermore, medication adherence plays a critical role in post-transplant survival 
because the medications prevent transplant rejection and severe side effects. However, 
adherence among alloHCT patients has received scant attention: The few available 
studies found greatly varying medication adherence rates ranging from 33% to 95% 
which could explain some variation in alloHCT patients’ survival (Morrison, Martsolf, 
Wehrkamp, Tehan, & Pai, 2017; Posluszny et al., 2018).   
Assessment of adherence to multiple medication regimens is challenging (Inauen 
et al., 2017). Various ways to measure adherence include: self-reports, pill counts by 
healthcare providers, pharmacy records, serum/urine drug levels, and an electronic 
monitoring system (Farmer, 1999; Inauen et al., 2017; Williams, Amico, Bova, & 
Womack, 2013). Though not without disadvantages, an electronic monitoring system, 
such as an electronic pillbox, allows for a more objective and precise real-time 
assessment by transmitting data signals, and it can be easily integrated into a patient’s 
daily life (Inauen et al., 2017; McGillicuddy et al., 2013). Only recently have studies 
integrated these devices into clinical care, e.g., for hypertension, HIV, kidney transplant, 
and diabetes (Davidson et al., 2015; Haberer et al., 2012; McGillicuddy et al., 2013; 
Welch, Balder, & Zagarins, 2015). This study sought to assess the feasibility of using an 
electronic pillbox to monitor adherence to multiple medications in patients after alloHCT 
in the first six months after hospital discharge. In addition, the study addresses the 





As part of a larger transplant study, individuals with leukemia and lymphoma 
cancers were followed for 180 days after their first hospital discharge. We tracked 
patients’ electronic pillbox use through real-time data transfer and also conducted semi-
structured interviews to learn about their experiences. The study was approved by the 
Institutional Review Board of Columbia University, including Teachers College, and the 
hospital from which the data were collected. All participants signed a written informed 
consent prior to participating in the study. The study referred to the reporting guidelines 
for qualitative studies and mixed methods (Creswell, Klassen, Plano, & Smith, 2011; 
O’Brien, Harris, Beckman, Reed, & Cook, 2014; Tong, Flemming, McInnes, Oliver, & 
Craig, 2012; Tong, Sainsbury, & Craig, 2007) and especially followed COREQ (see 
Appendix C for responses to all items of COREQ) for reporting the qualitative results 
(Tong et al., 2007). 
Setting and Participants 
The study was conducted at a renowned hospital located in an urban area. The 
location of the study site allowed diverse individuals to receive treatment. Eligible 
patients were adults with leukemia or lymphoma cancers who received an alloHCT at the 
hospital. Patients were eligible for the study if they were 18 years or older and spoke and 
read English, Spanish or Mandarin. Participation in the study was fully voluntary and was 
conducted only with eligible patients who had formally agreed through written informed 




Medication monitoring using electronic pillbox. The electronic pillbox used in 
this study was a wireless device (MedMinder, Maya, Inc, Needham, MA) with an internal 
cellular modem. It contained 28 compartments, suitable for up to 4 doses per day for 7 
days. Each compartment contained a removable cup. The pillbox transmitted a real-time 
signal to MedMinder’s server when the cup was removed. The electronic pillbox had to 
be switched on in order to transmit data. Due to limited battery time (approximately 30 
minutes), the device had to remain plugged into a regular 110V outlet for continuous 
signal transmission. As this was an observational study, the reminder functions of the 
system were not activated. Electronic monitoring system is known to be a novel and 
objective method of measuring adherence (Ruddy, Mayer, & Partridge, 2009).  
Interviews. The interviews were developed in order to best capture patients’ 
overall experience of taking multiple medications and their use of the pillbox using a 
narrative approach. A theory-driven interview guide was developed by the principal 
investigator, who is an expert in health psychology and has conducted many studies in 
this area. The interview guide covered different areas related to adherence after hospital 
discharge, including the use of electronic pillbox. The last section (Part 7) of the 
interview specifically asked about their experience using their pillbox. The exact wording 
of the questions is included in Appendix A. The interview guideline also contained 
probing questions to facilitate gathering of further information from the participant. To 
ensure the quality of the interviews, interviewers were trained by the principal 
investigator; the interview questions were pilot tested during role-play interviews prior to 
conducting actual interviews with patients, and interviewers were also allowed to shadow 
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interviews before they conducted an actual one. There was no relationship between 
researchers and participants prior to the study. All interviewers were female, and they 
hold either a bachelor’s or master’s degree in social sciences, public health or health 
sciences.  
Two independent coders analyzed seven randomly selected interviews (25% of 
the whole sample) using the NVivo to calculate inter-rater reliability (agreement between 
coders that each relevant theme had been mentioned across interviews). Kappa 
coefficient for pillbox benefits was 0.71, and the equivalent figure for pillbox challenges 
was 1.00, both exceeding 0.70, which indicates satisfactory inter-rater reliability.  
Procedures 
Patients were recruited during pre-transplant outpatient visits prior to admission 
for transplant or during the transplant hospitalization. Patients consenting to the study 
received an electronic pillbox pre-tested for functionality and were trained on its use as 
part of their discharge education plan. Per routine pre-discharge policy, all medications 
(dose, schedule, side effects, potential interactions) were reviewed with the patient by a 
pharmacist or a nurse. Electronic pillboxes were filled with medications and given to the 
patient at discharge. Patients were asked to use the electronic pillbox for 180 days and to 
keep the device plugged in at all times. The research team monitored pillbox signals 
remotely and approached patients at their routine hospital visits if their pillboxes were not 
working. If the pillbox remained plugged in but did not transmit a signal, the research 
team replaced the defective pillbox. Trained research assistants interviewed patients in 
pairs, one taking notes and recording, and the other conducting the interview, at 3 and/or 
6 months after discharge from the hospital. Interviews were conducted face-to-face in the 
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hospital while patients were waiting for their hospital appointments or through the phone 
if they were not able to make it to the hospital because of their physical condition. In 
some interviews, the caregivers were present with the participants as they accompanied 
the patients for hospital appointments. The interview lasted about 40 to 60 minutes. All 
interviews were audio recorded and transcribed, with personal identification information 
removed to protect the privacy of participants.  
Data Analysis 
Time to initiation of pillbox use. Signal transmission in the first 180 days after 
hospital discharge was analyzed, excluding days when the patient was readmitted to the 
hospital and medication was under clinical supervision.1 The research team checked the 
pillbox status daily on the device manufacturer’s website and coded days when at least 
one signal was transmitted. The initiation period of the pillbox was calculated from the 
first full day after the patient was discharged home to the first signal transmission.  
Period and rate of pillbox signal transmission. The period of signal 
transmission, when the device was switched on, was calculated based on the number of 
days between first and last signal transmission date. Then we calculated signal 
transmission rates as percentages (the number of non-hospitalized days with signal 
transmission as a percentage of the total number of non-hospitalized days). Signal 
transmission period and the rate of signal transmission of each pillbox were monitored to 
examine whether the pillbox functioned well, and as well as whether patients kept the 
pillbox on and for how long. 
                                               
1 For patients who returned the pillbox during the study, we limited the calculation until that day and for 




Duration of pillbox cap opening. The duration of pillbox cap openings (number 
of days between first and last pillbox opening) were counted based on the days when 
there was a signal transmission. It was examined to see whether the pillbox was actually 
in use in real time when the pillbox was kept on. We also calculated adherence score 
based on this measure.  
Adherence. Based on the assumption that patients open the pillbox to take their 
medications, we used pillbox cup openings to measure adherence. This is the most 
common method of measuring adherence using an electronic device. Adherence for non-
hospitalized days during the study period was calculated from the initiation of pillbox use 
(first signal transmission), following recommendations by Vrijens and colleagues (2012). 
The prescribed multiple medication regimen specified at least four daily doses (e.g., 8 am, 
2 pm, 8 pm, 10 pm). We calculated adherence for each patient based on the number of 
pillbox cap openings for up to 180 days after the initiation of treatment. Implementation 
was measured by first dividing each non-hospitalized day into two-hour windows, 
counting from 4:00 am to 3:59 am the next day to allow for late-night doses. We then 
checked each two-hour window to determine whether there was at least one cap opening. 
For each day, we counted the number of windows with at least on cap opening and 
divided it by 4 to calculate a daily adherence score.2 The daily adherence scores across 
the study period were used to arrive at the average adherence score for each patient (the 
sum of daily adherence scores/the number of days in the study period). 
Interviews. All transcripts were read carefully before pillbox-related quotes were 
extracted. The codebook that identified themes with definitions and examples was 
                                               2	We limited the number of windows with cap openings to 4, even though 21 patients exceeded this number 
at least once. We did so under the assumption that the number of doses prescribed to patients would 
realistically not exceed 4.	
23 
	
developed under the supervision of the principal investigator. For this study, coding was 
focusing on the two big themes: the benefits and challenges of using the electronic 
pillbox because we wanted to examine what participants found useful and challenging. 
Using content analysis, two independent coders categorized the extracted quotes into the 
two different themes: pillbox benefits and challenges. By further reviewing the quotes, 
the two coders categorize the quotes into different themes within benefits and challenges. 
Coding was initially done on excel, but also on NVivo 11 for more systematic analysis.   
Results 
Characteristics of Patients 
Participants (n = 33, 45.5% female, age: M = 54.18) had different ethnic 
backgrounds, with almost half of the sample (45.5%) reporting an ethnic minority 
background (Hispanic: 18.2%, Asian: 15.2%, African-American: 9.1%, Other: 3.0%) and 
the other half Non-Hispanic White background (54.5%). Most patients who used the 
pillbox participated in the interviews (n = 28) with nearly identical sociodemographic 
makeup (46.4% female, age: M = 53.97; ethnic minority group members: 46.4%).   
Feasibility of Using an Electronic Pillbox in Patients After AlloHCT 
During the study period (08/15/2012 – 07/15/2014), 84 adult patients received an 
alloHCT at the study site, which has an established cell transplant program. Some 
patients (n = 7, 8.3%) were ineligible for participation because of language barriers (all 
materials were available in English, Spanish, and Mandarin). The recruitment rate was 
high: Of the eligible patients (n = 77, 91.7%), about half (n = 38, 49.4%) agreed to 
participate and signed consent. Of the consented patients (n = 38), five patients did not 
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participate in the data collection: One patient died prior to discharge; one patient had a 
complicated recovery with repeated hospitalizations; and three patients withdrew from 
the study before discharge citing the size of the box and concerns about using it at home.  
The remaining patients (n = 33, 86.8%) each received an electronic pillbox. Of 
these, we did not detect any signal transmission from five patients (one patient used the 
pillbox without plugging it in, one was quickly readmitted to the hospital and passed 
away, two patients found it too cumbersome and decided not to use it after they received 
a pillbox, and one patient did not state a reason but chose not to use it). Most patients (n = 
28, 84.8%) used the pillbox as instructed and kept it plugged in to allow signal 
transmission. However, a technical problem resulted in loss of data for one patient, so the 
adherence rate was calculated based on 27 (81.8%) patients. The flowchart below 
illustrates the patient recruitment and data collection (see Figure 2.1).  
Pillbox Use and Signal Transmission 
The first pillbox signal for most patients (n = 25) was transmitted on the first day 
after patients took the pillbox home (initiation period: M = 0 days). The initiation period 
was calculated counting from the date of taking the pillbox home to the first signal 
transmission. A few patients (n = 3) took longer to start using the pillbox after they 
received it and took it home (M = 27 days). The period of pillbox signal transmission was 
calculated based on the number of days between the first and the last signal transmission 
date. The median number of days we received signals from patients was 196 with an 
interquartile range of 111 (IQR = 265 – 154). We received signal transmission from 
many patients beyond the study period. The average among these patients was 296 days 
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(n = 18/28 with a total of 5,328 days). The maximum number of signal transmission days 
was 503.  
The duration of actual pillbox use, which takes the difference between the first 
day of pillbox opening and the last day, was calculated to examine whether patients 
actively used the pillbox and for how long. The median number of days on which patients 
opened the pillbox was 180 with an interquartile range of 108 (IQR = 224 – 116). 12 of 
the 18 patients continued opening the pillbox beyond the 180 days (with a total of 2,829 
days and an average of 236 days). The maximum number of pillbox cap opening days 
was 326. The box plot in Figure 2.2 provides an overview of the pillbox use, including 
the interquartile ranges of signal transmission and pillbox cap opening days. It also shows 
the overall distributions of the initiation period, period of signal transmission and the 
duration of pillbox use using box plots. For analyses of signal transmission and adherence, 
we capped discontinuation at 180 days after the first transmission.  
Among the patients who used an electronic pillbox (n = 28), we found high 
variability in signal transmission rates ranging from 6-100% with an average of 68.1%. 
There were eight patients (28.6%) with transmission rates below 50% and 20 patients 
(71.4%) with higher than 50%. Among the patients who exceeded 50% of signal 
transmission rates, eleven of them (11 of 20) had high transmission rates between 90-100% 
(see Figure 2.3).  
Adherence Rate 
We calculated the adherence score (n = 27) based on the first 180 days after first 
pillbox use when signal transmission was active. The average adherence score was 2.2 
(55%) out of 4 with a median of 2.44 (see Figure 2.4). This means that patients, with the 
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option to open their pillbox caps at least four different times each day, actually did so 2.2 
times on average. Figure 2.5 shows pillbox cap openings of two patients with high signal 
transmission rates. Both of them consistently used the pillbox, mostly in the morning and 
evening to night. There is an observable gap for P35 when the patient was readmitted to 
the hospital.  
Patient-Reported Experiences with the Pillbox 
Most of the patients who received the pillbox (n = 28 of 33) participated in the 
interview. Interviews from five patients were missing: three patients were deceased, one 
patient was unavailable, and the other was too ill to participate in the interview (see 
Figure 2.1). Patients described their experiences of using the pillbox. Although they 
described some difficulties, their experiences were positive overall. The major themes are 
summarized as benefits and challenges associated with an electronic pillbox.  
Benefits of using an electronic pillbox. Common benefits discussed by patients 
were ease of use and integration into everyday life, pill organization and storage, memory 
facilitation, and reminders for refills and dosage.  
Ease of use and integration into everyday life. Patients were asked about ease of 
use and integrating the pillbox into their daily lives. Some patients (n = 8/28, 28.6%) 
experienced no issues with the pillbox and found it easy to use. Patients appreciated the 
layout of 28 small containers, which reminded them to take medications four times a day 
for seven days. “I like the way it was broken up into times. Rather than just morning, 
evening, and night. That I liked.” (P40, age 57, male). Other patients (n = 4/28, 14.3%) 
explicitly mentioned that they liked the removable containers. Patients were able to take 
the container from the pillbox and turn it upside down so that medication fell into their 
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palms, rather than reaching into the pillbox. With the little cup, they could carry their 
medications between rooms. For example, one patient reported: “You could take the 
container out. [It is] easy to take pills out.” (P01, age 66, male). Another patient reported: 
“I liked the canisters because I was able to take them out.” (P38, age 64, female). 
Moreover, though the others did not verbalize, some patients (n = 4/28, 14.3%) 
specifically mentioned they are content with the size of the removable cups.  
Patients commonly reported keeping their pillbox in a central location at home, 
most frequently the kitchen (n = 11/28, 39.3%), bedroom (n = 8/28, 28.6%), or living 
room (n = 3/28, 10.7%). Some patients reported multiple locations for different doses (n 
= 6/28, 21.4%). Its design allowed patients to integrate the pillbox into their daily lives. 
One patient mentioned,  
(…) the pillbox design is pretty simple. It is elegant so…it doesn’t look like it’s a 
something that reminds you that it’s medication, so psychologically when you’re 
looking at it you wouldn’t mind having it on display. (P20, age 50, male)  
 
Many patients (n = 13/28, 46.4%) reported refilling pillboxes once a week, 
typically on weekends (n = 7/28, 25.0%). For example, one patient reported,  
I’ve been pretty good about that because the weekly, putting [medications] in the 
pillbox every week gives me some structure, so I know which ones I’m going to 
run out of. (P35, age 65, female)  
 
However, other patients may not have reported the frequency of refills accurately. For 
example, P08 (age 53, male), who was interviewed in the presence of his wife, reported: 
“Yes, I always refill my box on Sunday, and I always take my medicine.” His wife 
interrupted,  
No, you don’t. He fills the box too often. I tell him not to refill the box until the 
end of the week. If compartment is empty, then he [will] know [whether he took 
them or not]. [But] he will refill it right after he takes it and when he goes back 




Pill organization and storage. Patients (n = 10/28, 35.7%) reported that they used 
the pillbox as a place to store medications. When the patients were discharged from the 
hospital, they were provided with 18 or more pill bottles, a list of medications, and daily 
schedules of dosage. The multiple-medication schedule in this population is complex, and 
it took most patients and caregivers time and effort to understand it. Having a pillbox that 
laid out the appropriate medication for the week eased patient burden, minimized 
potential for error, and allowed patients time for other activities. For example, one 
mentioned,  
It was nice to have the medication lined up for the whole week. I liked the layout 
of it and I knew that once I filled it each week I was getting my medication I 
wasn’t making a mistake, so I found it very good for that. (P38, age 64, female)  
 
Another reported,  
I like it, I think it helps me get organized. You know it’s visual, so you can see 
things. It’s yeah, it’s good to be able to see everything spread out. (P35, age 65, 
female)  
 
Memory facilitator. Patients (n = 10/28, 35.7%) found that the pillbox helped 
them remember to take their medication and provided them with information on whether 
or not they had taken their medications. One reported, 
That if I’m not sure every now and then and say did I take that or not? You know 
did I take that 2 o’clock magnesium tablet and if I have the pillbox and if I have 
everything set up for the week then I’d be able to look in the pillbox and see if it 
is empty or not. (P28, age 59, male)  
 
Another reported,  
Even the little green light, you can’t miss that. Like I say, honestly I don’t forget 
to take my medication but sometime even if I neglect it so every time I come to 
the room and I see that light, I say okay that’s something that have to do with 




Recognizing the need for refills in time. Filling the pillbox with one week of 
medications helped patients recognize when refills were needed (n = 8/28, 28.6%). This 
task is important in managing multiple medications that run out at different times. For 
example, a patient, whose husband helped with managing her medications reported: “[My] 
husband orders pills. When some are low on Sundays, he calls the pharmacy and gets 
refills.” (P07, age 56, female). 
Potential for reminder systems. The current study was designed as an 
observational feasibility study rather than an intervention study, so the built-in reminder 
functions such as flashing lights, acoustic alarms, text messages and calls were not 
activated. Yet, patients (n = 6/28, 21.4%) commented that such features would be useful: 
“Oh I needed to have something (…) an alarm to remind me of the time.” (P35, age 65, 
female).  
Challenges of using an electronic pillbox. Patients also encountered several 
challenges, such as the pillbox’s size, lack of personalization, and issues with the 
charging cord and wireless connection.  
Size and portability of the pillbox. The large size of the pillbox was found to be a 
challenge (n = 9/28, 32.1%). A patient reported,  
It’s hard to relocate my pillbox to where it used to be because other items have 
(…) cluttered [in] that space and I just haven’t had time to organize. It just 
became a little difficult to use the pillbox. (P19, age 46, male)  
 
Another patient mentioned: “(…) the pillbox is kind of big and heavy, so I wish they will 
have a smaller one.” (P29, age 63, Female). 
Portability was also mentioned as a challenge (n = 6/28, 21.4%).  
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Sometimes I skip just because I’m not around, but not intentionally. Or sometimes 
I just forget or go past the time. I’m not always at home and everything, and this 
pillbox is pretty big and I can’t bring it everywhere. (P20, age 50, male)  
 
Another patient reported: “And it’s too big to take anywhere with you, you know? I mean 
like if you’re going anywhere.” (P40, age 57, male). Frequent follow-up visits to the 
hospital are required for these patients after transplant to monitor their condition. 
Appointments may take several hours, often overlapping with medication doses. When 
patients were recovering and went back to work and travel, they found it difficult to use 
the pillbox. Only one patient (n = 1/28, 3.6%) mentioned that he carried the pillbox 
wherever he went, and many (n = 11/28, 39.3%) mentioned carrying the pills only, 
emphasizing the need for portability. We observed patients carrying the pillbox in large 
bags or plastic bags during clinic appointments. Other patients resorted to “pocket-
dosing”: “So in the morning I’ll separate all of them, put it in the pillbox then I’ll take the 
morning pills. Then I just shove it in my pocket and go about my day.” (P40, age 57, 
male).  
Number and size of cups for medication doses. Patients often requested a smaller 
pillbox, yet also enough space for their multiple-medication regimens. Although most 
patients found the removable cups to be generously sized, some found them to be too 
small (n = 4/28, 14.3%). The pillbox currently provides four cups per day, labeled as 
Morning, Noon, Afternoon, and Evening, but sometimes patients have to take more than 
four doses per day. Some (n = 5/28, 17.9%) patients commented that adding more cups 
would be useful for managing their medications. For example, one reported: “Pillbox is 
[too] small to fill it up, [it needs] more variety, [and] more slot[s].” (P11, age 71, female). 
Another reported changes in his medication regimen,  
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My pills have fit in the compartments. The complication is that sometimes 
[members of my treatment team] add meds that don’t fit in the 4 periods. 
Sometimes I have 6 periods. Pills that I can’t fit in the pillbox. Late morning pills 
or late afternoon pills, if required, have to stay outside the pillbox. (P19, age 46, 
male)  
 
One even suggested using two: “It would have been better to have two sets.” (P25, age 66, 
male).  
Medications that cannot be stored in the pillbox. The current device does not 
offer a system to accommodate medications that do not fit in the removable cups, such as 
liquid medications or other dosing regimens such as powder packets, making it more 
difficult for patients to remember those medications (n = 3/28, 10.7%). A patient reported: 
“I had 2 liquids, you can’t put it in the box, but you have to be aware that you have to 
take it.” (P13, age 67, male). Another reported: “I take [a liquid medication] but I 
couldn’t really utilize it for the pillbox because it was in liquid form. So that’s another 
thing about the pillbox that I didn’t like.” (P20, age 50, male).  
Power source, battery life, and wireless signal. Connecting the pillbox to a 
constant power source and wireless signal proved to be a challenge for patients (n = 5/28, 
17.9%). The device had a short battery life of 30 minutes, so constant charging was 
necessary. When a patient was asked what he did not like about the pillbox, he answered: 
“Battery stopped working.” (P20, age 50, male). The short battery life limited the patients’ 
ability to move the pillbox to locations where an electrical outlet was not available. “Yes 
with traveling [I had an issue with keeping the box plugged in].” (P10, age 48, Male). 
Some patients (n = 3/28, 10.7%) struggled to keep a constant Internet connection, as the 
pillbox did not detect wireless signals. “I think my signal wasn’t good for everybody else. 




This study demonstrated the feasibility of using an electronic medication 
monitoring device with cancer patients taking multiple medications. The recruitment rate 
was high, with one in two eligible patients participating. Most of the consented 
participants used the pillbox as instructed, allowing for signal transmission and remote 
monitoring of adherence. However, the signal transmission rate varied greatly among 
patients, with only one in three participants showing high signal transmission rates that 
would be essential for developing real-time interventions to improve adherence.  
The adherence rate of cancer patients after alloHCT (55%) is comparable to that 
reported by the WHO (Sabaté, 2003) for other patients with chronic conditions (50%) and 
also falls within the range of adherence (33% - 95%) observed in patients with 
hematopoietic cell transplant in a recent review (Morrison et al., 2017). Another recent 
study similarly found suboptimal adherence rates (71% for taking immunosuppressants 
and 71% for taking other pills) (Posluszny et al., 2018). These results suggest the need for 
more research into multiple mediations adherence among patients with chronic conditions. 
This was the first study to examine cancer patients’ adherence to multiple 
medications using an electronic monitoring system. Though not without some challenges, 
the reported experiences from 28 alloHCT patients who used the electronic pillbox were 
positive overall. Eighteen patients continued using the pillbox beyond the 180 days. This 
suggests that an electronic pillbox can be used to study multiple medication intake in 
cancer patients, even when the medication regimen is highly complex, and patients suffer 
from high morbidity. The study not only reports quantitative outcomes from the 
electronic pillbox, which is known to be a more objective measure (Ruddy, Mayer, & 
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Partridge, 2009), but also reports patients’ lived experiences while using the electronic 
pillbox.  
The study has a number of limitations. First, this study was conducted at an urban 
hospital with a limited number of patients. While there was good representation of male 
and female patients and the diverse age and ethnic background speak to the potential 
generalizability of the results to other urban areas, future research with larger samples 
drawn from other regions is needed. Second, the implicit organization system of the 
pillbox prevents it from being purely observational. The layout of the pillbox promotes 
planning for a whole day’s doses and up to one week at a time. Therefore, the adherence 
rates in this study are likely an upper bound of the adherence rates we would find without 
this organizational system.  
Theoretical and Practical Implications 
The current study has theoretical and practical implications relevant to both 
researchers and clinical practitioners, showing that an electronic medication monitoring 
system is feasible to use for patients taking multiple medications. Regarding theory, we 
suggest the addition of technological support as a facilitator for adherence in addition to 
social support, an established facilitator (DiMatteo, 2004). For example, the Information-
Motivation-Behavioral Skills model proposes that individuals with adequate adherence 
information, motivation (both personal and social), and behavioral skills demonstrate 
better adherence and more positive health outcomes (Fisher, Fisher, Amico, & Harman, 
2006). The current study indicates that theoretical models should include technological 
support in addition to social support, which could be based on the data from an electronic 
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pillbox. Technological support can enhance each of the three components of the IMB 
model, information, motivation, and behavioral skills, and facilitate adherence by 
delivering a timely intervention when adherence problems are occurring. At the same 
time, there is considerable room for improvement in the devices available. Patients and 
the research team encountered a number of challenges in using the electronic pillbox. 
Therefore, we delineated a set of criteria for an ideal electronic monitoring system for 
multiple medication regimens in clinical practice and research.  
Pillbox Design Suggestions 
An updated pillbox would come in several sizes to accommodate patients’ 
varying number of medications (28 compartments were suitable for the complex 
medication regimen in our population). Each compartment would have a built-in sensor 
to detect opening and closing and an additional sensor for the lid to assess refills. Patients 
could also personalize the labels for each compartment and store prescription instructions 
in the lid. To store the medications that do not fit in the pillbox (e.g., liquids, powder 
packs), an updated device would come with an additional sensor-equipped box that 
communicates with the electronic pillbox. The updated pillbox would be light-weight yet 
sturdy with clear lids for the whole box and for each compartment. It could be locked to 
prevent children or family members from inadvertently taking medications. It would have 
a charger cable that connects securely. 
Portability. The updated device would come with a carrying bag and a portable 
single-day supply that contains sensors and communicates with the pillbox; one possible 




Facilitating the set-up at home. A plug-and-play design would be best, as it is 
easy to use and intuitive to set up. It is important for less digitally literate populations, 
such as older patients. The electronic pillbox would have a phone line to support set-up at 
home. An ideal electronic pillbox would have built-in real-time wireless data 
transmission to a cloud server, with the possibility to connect with a local wireless 
network if the wireless phone signal at home is not consistent (e.g., in rural areas and in 
homes with poor cell phone reception). Battery life should be 24+ hours. 
Reminder system. The pillbox would have an optional reminder system (such as 
a sound or light signal) that reminds the patients or caregivers at the dosing time and 
responds when the medication is taken. If medication is not taken within the two-hour 
window of the prescribed dosing time, patients or caregivers would receive text, email, or 
phone reminders. We observed that many patients do not display a time-anchored 
adherence pattern but rather have flexible wake-up times that anchor the day’s 
medication intake. Therefore, we would recommend integrating a mobile phone sensor 
that starts the day when patients wake up.  
Data storage and visualization. There was data loss for a patient because the 
website did not retain the data. A cloud service that stores data for at least 12 months that 
is encrypted, and password protected would aid patients in monitoring their adherence 
over longer durations and sharing data with their healthcare providers. Data storage on 
the device or link with a cell phone application is another way of storing data. A 
smartphone application would allow patients to easily receive updates on medication 
schedule and minimize data loss in case of battery failure. It would connect with medical 
prescription systems so that updates are suggested automatically, and patients could 
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accept and modify them after medical appointments. Moreover, it would facilitate data 
visualization for patients and caregivers by showing adherence patterns over days, weeks, 
and months, with missed doses clearly labeled.  
Conclusion 
Despite the challenges encountered, most patients attempted to use the pillbox and 
were able to use it satisfactorily. This suggests that an electronic pillbox is an acceptable 
means of tracking adherence to multiple medications and that there is great promise for 
sensor-based assessment for multiple medication regimens. Based on this study, it will be 
possible to develop a suitable pillbox for patients prescribed with multiple medications. 
Future work might explore this technology and its uses for other chronic conditions 
where complex medication regimens are prescribed. Additionally, studies may utilize the 
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Figure 2.2. Overview of pillbox use: Time to initiation of pillbox use (number of days 
between first day at home after pillbox receipt and first signal transmission), period of 
pillbox signal transmission (number of days between first and last signal transmission 
date), and duration of pillbox use (number of days between first and last pillbox opening)  
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Figure 2.3. Signal transmission rates (% of non-hospitalized days during the first 180 
days after hospital discharge) of alloHCT recipients (n = 28), with 50% signal 































Figure 2.4. Adherence score of alloHCT recipients who used pillbox (n = 27; average 
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SOCIAL SUPPORT FOR ADHERENCE TO MULTIPLE MEDICATIONS:   
WHAT HEALTHCARE PROVIDERS  
AND CLOSE OTHERS DO TO HELP PATIENTS 
Abstract 
Background: Social support plays an important role in improving health outcomes, 
including medication adherence. However, social support for multiple medication 
regimens has been understudied despite the increasing prevalence of multiple medication 
regimens, advances in medicine, and longer life expectancy. Recipients of allogeneic 
hematopoietic cell transplant (alloHCT) are required to take multiple medications after 
transplant to prevent transplant rejections and complications.  
Objective: The objective of this study was to examine the types of social support that are 
available to alloHCT patients from their caregivers and healthcare providers.  
Methods: Through semi-structured in-depth interviews, 28 patients after alloHCT (46.4% 
female, age: M = 53.97, 46.4% ethnic minority) shared their experiences of taking 
multiple medications and managing adherence tasks. Coding categories for content 
analysis were developed based on the Information-Motivation-Behavioral Skills (IMB) 
model and prior research distinguishing practical, emotional and informational support. 
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Results: Individuals after transplant received support from both healthcare providers and 
a range of lay caregivers, most frequently spouses, partners and other family members. 
Having a relationship of trust with healthcare providers was important for patients after 
alloHCT; it encouraged and comforted patients to follow their instructions and medical 
decisions. Healthcare providers mainly fulfilled their medical need and provided 
informational support, while lay caregivers were the main source of emotional and 
practical support. The role of lay caregivers extends to different areas of patients’ daily 
lives that are related to medication adherence, including support for attending doctor’s 
appointments, managing medications, and sustaining a healthy diet. Furthermore, they 
were sources of financial support.  
Conclusion: Support from healthcare providers is critical and the basis for patients’ 
adherence at home. A dedicated lay caregiver is required for patients after alloHCT to 
follow their multiple medication regimens. The findings highlight the necessity for 
healthcare providers and lay caregivers to work in tandem to support patients’ adherence 
to multiple medications.  
 
Keywords: allogeneic hematopoietic cell transplant; cancer; caregiver support; 




Adherence to multiple medications is a daily struggle for a growing number of 
people due to the increasing availability and complexity of oral medications for treating 
chronic conditions, such as cancer (National Center for Health Statistics (US), 2014; 
Sabaté, 2003). Individuals reporting the use of prescription drugs increased from 51% to 
59%, while those reporting the use of five or more prescription drugs increased from 8.2% 
to 15% from 1999 to 2012 (Kantor, Rehm, Haas, Chan, & Giovannucci, 2015). But only 
about 50% of patients adhere to their prescribed medication regimens (Bosworth, 2010; 
Sabaté, 2003). For patients who are prescribed three or more daily medications, 
adherence may pose a particular challenge: Adherence declines as the number of daily 
doses increases (Claxton, Cramer, & Pierce, 2001; Pantuzza, Ceccato, Silveira, Junqueira, 
& Reis, 2017). 
Social support has long been recognized as a key contributor to mental and 
physical health (Berkman, Glass, Brissette, & Seeman, 2000; Holt-Lunstad, Smith, & 
Layton, 2010; Uchino, 2006). It is associated with a higher quality of life—and even 
survival—in cancer (Aizer et al., 2013; Chou, Stewart, Wild, & Bloom, 2012; 
Luszczynska, Pawlowska, Cieslak, Knoll, & Scholz, 2013). A longitudinal study with a 
large sample found alloHCT patients who received pre-transplant emotional support had 
higher rates of post-transplant survival (Ehrlich et al., 2016). However, because it is a 
broad construct, there are different ways of measuring social support (Helgeson, 2003). 
Structural measure refers to the existence of social ties and networks (e.g., marital status, 
living with somebody or not, and having a family or not), whereas functional measure 
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refers to the types of support, which usually include practical, emotional, and 
informational support (Helgeson, 2003; House, Kahn, McLeod, & Williams, 1985). 
Instrumental support refers to actual physical or material help; emotional support refers to 
love, care, value, empathy, and encouragement; informational support refers to factual 
knowledge, and certain types of support work more effectively in some situations than 
others (Cohen & McKay, 1984; Cutrona & Russell, 1990; Helgeson, 2003; Thoits, 2011).  
Social support is also related to medication adherence. Reviews of the existing 
literature, which examined both structural as well as different functional support 
categories, found that social support, especially practical support provided by close others, 
is linked to better adherence (DiMatteo, 2004; Scheurer, Choudhry, Swanton, Matlin, & 
Shrank, 2012). Social support for medication adherence has also been studied in chronic 
conditions, such as HIV/AIDS, diabetes, and cardiovascular diseases (Berghoff et al., 
2018; Kelly, Hartman, Graham, Kallen, & Giordano, 2014; Simoni, Frick, & Huang, 
2006; Mayberry & Osborn, 2012; Zullig et al., 2015). These studies also reported a 
positive correlation between social support and adherence. A recent study of 
hematological cancer patients found that higher levels of social support were associated 
with higher rates of medication adherence (Hall et al., 2016). Moreover, the most recent 
study, which closely resembles the present study in its population of interest, examines 
adherence to a variety of post-transplant tasks as undertaken by patient-caregiver dyads, 
including medication adherence (Posluszny et al., 2018).  
Since the 1990s, the number of individuals receiving alloHCT has increased, 
significantly improving the survival rate of patients (Hahn et al., 2013; Majhail et al., 
2015). Nevertheless, even following a successful transplant, individuals experience high 
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mortality due to potentially life-threatening complications, infections, graft-versus-host 
disease, and cancer recurrence (Holtan et al., 2015; Pasquini, Wang, & Schneider, 2009). 
The multiple medication regimen is prescribed to improve survival rates (Morrison, 
Martsolf, Wehrkamp, Tehan, & Pai, 2017). However, in part due to the complexity of this 
regimen and other personal and social factors, the rate of adherence has not been ideal. In 
a recent pilot study, 54.6% of alloHCT patients were found to be poorly adherent to their 
medication regimens (Lehrer et al., 2018). A 2014 study found that almost two-thirds of 
alloHCT patients were non-adherent in taking their immunosuppressants, the most 
essential of post-transplant medications (Kirsch et al., 2014).  
Because receiving a hematopoietic transplant is a long, aggressive and exhausting 
process, many transplant programs require a caregiver for transplant eligibility, in line 
with national and international guidelines (National Marrow Donor Program, 2017; 
Tomblyn et al., 2009). Individuals often experience depression and fatigue after receiving 
an alloHCT (Jim et al., 2016). However, those who receive support from their caregivers 
tend to fare better psychologically and physically; studies on alloHCT patients 
specifically identify caregivers’ support as a powerful factor of survival after transplant 
(Foster et al., 2005; McLellan et al., 2011; Rini et al., 2011). Moreover, a systematic 
literature review examined the relationship between social support and survival (Beattie, 
Lebel, & Tay, 2013). Of the six studies included in the review, five published studies 
found a link between social support and survival, while one unpublished dissertation with 
the largest sample size did not find any association between social support and survival 
(Beattie et al., 2013).  
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 While these are suggestive findings, studies on the role of healthcare providers are 
limited (Hall et al., 2016), and the role of social support for adherence to a multiple 
medication regimen could also benefit from additional study. Thus, we sought to 
investigate how healthcare providers and lay caregivers help individuals after alloHCT 
adhere to a multiple medication regimen and what concrete actions they can take to 
enhance adherence.  
Methods 
This study was part of a larger transplant study that followed individuals with 
leukemia and lymphoma cancers for 180 days after their first discharge from the hospital. 
This study, based on directed content analysis (Hsieh & Shannon, 2005), uses a theory-
informed qualitative approach to identify the types of support patients received. 
Individual semi-structured interviews were conducted between three to six months after 
hospital discharge. The use of human subjects was reviewed and approved by the 
Institutional Review Board of Columbia University, including Teachers College, and the 
hospital from which the data were collected. All participants provided written informed 
consent prior to participation. The study referred to the relevant standards for reporting 
qualitative results (Creswell, Klassen, Plano, & Smith, 2011; O’Brien, Harris, Beckman, 
Reed, & Cook, 2014; Tong, Flemming, McInnes, Oliver, & Craig, 2012; Tong, Sainsbury, 




Setting and Participants 
The study took place at a large urban teaching hospital, which provides a diverse 
population with access to healthcare, and is known to have a well-established hematology 
oncology and transplantation program. Eligible patients were invited by healthcare 
providers to participate in the interview during appointments. Individuals were eligible 
for the study if they were at least 18 years old and spoke English, Spanish or Mandarin. 
Two of the interviews were conducted in Spanish (7.1%), the rest in English (n = 26, 
92.9%) and none in Mandarin. Participation was voluntary. All patients received 
allogeneic bone marrow transplants and were prescribed a multiple medication regimen.  
Measures 
Semi-structured in-depth interviews were conducted. Interviewers followed a 
structured interview guide listing questions and probed individuals for detailed answers 
about their medication adherence and social support. The interview guide was developed 
by the principal investigator, who is an expert in health psychology. The guide outlines in 
detail a theoretically-informed qualitative approach to interpreting patient interview data. 
Interview questions covered various domains related to individuals’ overall medication 
adherence behaviors, including questions on social support (e.g., “Are there people in 
your life who support your taking medications?”). Part 2 and some elements of Part 6 
specifically asked questions about social support and patients’ relationships with 
caregiver and healthcare providers. The interview guide also contained probing questions 
to be used if the original question was not applicable to an individual. To ensure the 
quality of the interviews, interviewers were trained by the principal investigator; the 
interview questions were piloted tested during role-play interviews prior to conducting 
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actual interviews with patients. All research assistants at the time had a bachelor’s or 
master’s degree in social sciences, public health or health sciences. 
To assess inter-coder reliability, two coders selected seven interviews (25% of the 
sample) at random to code independently and calculated the Kappa coefficient in a binary 
fashion, assessing whether the coders agreed that the relevant theme had been mentioned 
in the randomly selected interviews. Kappa coefficients for support from lay caregivers 
and support from healthcare providers were calculated separately. The initial Kappa for 
lay caregivers’ support was in perfect agreement (κ = 1.00) and that for lack of lay 
caregivers’ support was 0.71, which is satisfactory inter-rater reliability. Initial Kappa for 
support from healthcare providers was 1.00, but that for lack of support from healthcare 
providers was 0.43. Discrepancies were discussed between the two coders until 
agreement was reached, especially the quotes on the lack of healthcare providers’ support. 
After discussing and clarifying the discrepancies, Kappa for the lack of support from 
healthcare providers increased to 0.71. All interview transcripts and relevant quotes were 
carefully read again by one of the researchers to calculate the number of patients that had 
mentioned the theme at least once and its percentage.  
Procedures 
Participants who agreed to participate in the study and signed written informed 
consent forms were contacted in advance to schedule each interview. Interviews were 
conducted either in person before doctor’s appointments and/or via telephone when 
participants could not manage hospital visits or simply preferred telephone interviews. In 
some cases, the caregiver also joined the interview when accompanying the participant to 
appointments. Interviews lasted from 40 to 60 minutes and participants could take a break 
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if desired. All interviews were conducted by two interviewers, with one interviewer 
asking questions and the other taking notes and recording the interview. All the 
interviews were audio recorded and transcribed. Data were kept in a secure password 
protected drive. Every participant was aware of and agreed to being recorded. All 
confidential information in the interview transcripts was removed and replaced with 
generic titles (e.g., nurse Jane Doe with Nurse 1).  
Data Analysis 
Directed content analysis was used to analyze the data (Hsieh & Shannon, 2005). 
Social support, which also falls under “social motivation” in the Information-Motivation-
Behavioral Skills (IMB) model (Fisher, Fisher, Amico, & Harman, 2006) and social 
support theory (Cohen & McKay, 1984; House et al., 1985; Thoits, 2011; Weiss, 1974), 
was the basis of the coding scheme. This study examined support received from both lay 
caregivers and healthcare providers, and the types of support, including emotional, 
instrumental, and informational support. A codebook was developed listing different 
themes, definitions, and examples (see Appendix B). Relevant quotes indicating support 
or the lack thereof were coded.  
Among the 28 interviews analyzed, data on support from healthcare providers 
were missing for two of them because the participants felt too sick or could not finish the 
interview. Thus, percentages are calculated based on 26 interviews for that specific 
category. All interview transcripts were read carefully. Two independent coders manually 
extracted the quotes onto an excel spreadsheet to code, and the same procedure was 
repeated in NVivo version 11. This software allows the creation of categories and 
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subcategories, comparing the coding between groups of people and calculating 
frequencies and discrepancies.  
Results 
Characteristics of Patients 
In total, 28 individuals (46.4% female, age: M = 53.97) participated. The sample 
was ethnically diverse, with almost half of the participants coming from a minority 
background (n = 13, 46.4%), (Non-Hispanic White: 53.6%, African American: 7.1%, 
Asian: 17.9%, Hispanic: 17.9%, other: 3.6%).  
Healthcare Providers 
We found that all participants asked about healthcare providers (100% of 26 
interviews) identified them as a source of support. Participants referred specifically to 
doctors and nurses when speaking about healthcare providers who provide medical care 
and treatment. At the hospital, clinical teams, including hematologists and nurse 
practitioners, worked closely together. Therefore, most individuals after transplant 
perceived them as a team (n = 22/26, 84.6%).  
Nearly all individuals reported having a good relationship with their healthcare 
providers and evaluated the relationship as positive (n = 24/26, 92.3%). The quality of the 
patient-healthcare provider relationship influenced individuals’ health behaviors, 
especially with regards to making medical decisions. When patients built trusting 
relationships with their healthcare providers, they felt confident following their 
healthcare providers’ guidelines. One individual mentioned, “I’m a believer, I believe in 
him. First thing we do in any situation that you wanna get help you have to believe. I 
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believe in him. So what he says is right.” (P17, age 50, male). Another individual also 
mentioned,  
Very simply, they have my best intentions in mind, and they override what do you 
call it...they know what the right thing to do is, whether I like it or not. So they’re 
not sticking me with bad tasting medications on purpose to make me feel bad. 
This is the right thing to take. They’re the experts, they know the conditions, they 
know what’s coming. (P13, age 66, male)  
 
At the same time, one participant (n = 1/26, 3.8%), while mentioning he did 
receive some support from his healthcare providers, also expressed that he had received 
too little information at the discharge meeting and was therefore dissatisfied with the 
healthcare providers. He said,  
I ended up back in here [admitted to the hospital]. They didn’t talk about 
hydration. (…) Hydration is likely a bigger deal than they tell you about. I was 
back in for 12 days. I was berserk about that. (P01, age 65, male) 
 
Another patient was ambiguous in her response regarding the relationship with healthcare 
providers and did not quite perceive a relationship: “Well, I have not had problems with 
them. I don’t care.” (P12, age 53, female). 
Types of Support from Healthcare Providers  
 Individuals after transplant perceived that their healthcare providers mostly 
provided informational support in line with their expertise. However, many individuals 
mentioned that they also received other types of support from the healthcare providers, 
including emotional support. We will present specific examples detailing the kinds of 
support provided and how they helped patients after transplant.  
Informational support from healthcare providers. Individuals after transplant 
mostly received informational support from healthcare providers (n = 23/26, 88.5%). A 
wide spectrum of healthcare providers, including pharmacists, dietitians, hematologists 
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and specialist nurses, provided informational support verbally and in writing. Patients 
received information on medications (n = 23/26, 88.5%) and nutrition, including 
hydration (n = 6/26, 23.1%).  
One participant reported that the relationship with healthcare providers made it 
easier to take medications.  
Because they tell me exactly that I need to take them, why I need to take them, 
yeah always teaching. Always teaching, yup. Every single day, every single 
appointment. The nurse coming first goes over all of the medication and the 
doctor will do the same thing. (P22, age 34, female)  
 
Support for medical needs. Many patients reported that their health providers 
met their medical needs, which required professional skills (n = 18/26, 69.2%). One 
individual mentioned, “They make sure that all my medical needs are met so I can 
recover and go back to a regular life.” (P14, age 32, male). Another patient recalled the 
help she received when she forgot to refill her medications on time and needed an 
immediate supply. “I have run out of the Prograf and that is very important, but the 
doctors called in a four-day refill script to [name of pharmacy 6] and I picked it up.” (P31, 
age 44, female). Often, support for medical needs was combined with emotional support, 
as a female participant reported in dealing with her difficult stage four graft-versus-host 
disease. She said,  
One of the reasons, I have to tell you, are the [name of hospital 1] nurses. They 
are angels. They packed me in ice at night. They looked at me, my skin was 
peeling, you couldn’t touch me any place without me screaming because it hurt so 
much. It’s very good to have nurses that are so kind. They actually stayed with me. 
They didn’t have to do more than just come when I rang the bell. It’s harder at 
night because everything is so quiet, and nothing can distract you from the pain. 
(P07, age 55, female) 
 
Emotional support. Healthcare providers, usually nurses, encouraged individuals 
after transplant and showed care for their personal lives (n = 9/26, 34.6%). The attitude of 
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healthcare providers and the way individuals after transplant perceived them influenced 
them in their recovery process.  
In the sense that they know things are important, they make me feel like my 
recovery is important, they make sure that all my medical needs are met so I can 
recover and go back to a regular life. (P14, age 32, male)  
 
Another participant said,  
I think the best thing was speaking with all the nurses. Becoming friendly with 
them. (…) Yeah, and the day I left the hospital was my birthday and they brought 
me a birthday cake. I can’t believe they did that! So that was nice, that brightened 
up my day. (P43, age 50, female)  
 
Although emotional support might not have directly influenced patients’ medication 
adherence, it contributed to a good and trusting relationship with healthcare providers, 
encouraging and helping individuals after transplant to recover. 
Lay Caregivers 
Lay caregivers, such as family members and friends, were the primary source of 
social support for transplant recipients. All participants reported receiving support from 
family members, friends, or acquaintances (n = 28/28, 100.0%). Moreover, about half of 
the participants reported to have at least one primary source of support, usually a spouse 
or partner, who was their main caretaker over the course of the transplant (n = 15/28, 
53.6%, see Figure 3.1). For example, a participant mentioned that his wife supported him 
in taking his medications (P13, age 66, male). Another participant mentioned, “My 
husband does everything! He’s actually on top of everything more than I am.” (P07, age 
55, female). 
A considerable number of transplant recipients (n = 11/28, 39.3%) reported 
relying on several lay caregivers, such as the partner and other family members (n = 6/28, 
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21.4%), family members other than the partner (n = 4/28, 14.3%), or family members 
and friends (n = 1/28, 3.6%). One of the participants mentioned that his whole family 
ensures that he takes his medications regularly on time (P14, age 32, male). Another 
participant mentioned,  
Well, yes my mother, I talk to her every day, three times a day, again my son, my 
boyfriend, (...) so yes, I have a lot of people supporting me, asking me this, did I 
do this. (P31, age 44, female) 
 
Additionally, in two cases, acquaintances or non-family members supported 
individuals after transplant as lay caregivers (n = 2/28, 7.1%). One of them mentioned,  
The helpers are mainly people from my [place of worship]. I have a woman who 
accompanies me to all my visits. Since my first transplant she has gone to every 
appointment with me. She brings lunch and meals and snacks. And uh, there’s a 
team of persons who provide me what I need in terms of food and stuff like that. 
So they’ve been very helpful. Um…I have a staff. A secretary, a bookkeeper, a 
staff in the kitchen. They do parts just to make sure. To get my car moved, get my 
mail, someone to go to the bank. So they take care [of] all those things. (P19, age 
46, male)  
 
Regardless of the type of their connection to the patient, lay caregivers are essential for 
post-transplant recovery.  
Types of Support from Lay Caregivers 
Lay caregivers supported individuals after transplant in various ways, including 
instrumental, emotional, and informational support. We will present each type of support 
with examples.  
Instrumental support. Lay caregivers had a wide range of tasks to help the 
patients with, including helping with taking medications or daily chores, such as cooking 
and cleaning.  
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[My] husband does all the homework. He cooks, I don’t. Doctor doesn’t want me 
to have outside food. He reminds me to take the medication, he reminds me 
almost every time. (P11, age 71, female) 
 
Instrumental support for medication intake. Individuals after transplant must 
take numerous medications even after a successful transplant and discharge from the 
hospital. Medication-related tasks are critical yet difficult for individuals after alloHCT 
due to the number and complexity of medications. Nearly all individuals in the sample (n 
= 26/28, 92.9%) mentioned that their lay caregivers helped with medication-related tasks, 
such as taking medications, reminding of doses, refilling, and picking up the medications.  
Every two three hours I have to take the medication. I have to be aware of the 
time and take and my husband reminds me. In 6 months, I have only missed one 
tablet. (P11, age 71, female) 
 
She also mentioned that she was able to refill medications on time because of her 
partner’s support: “[My] husband calls the pharmacy, they send us FedEx.” (P11, age 71, 
female). 
Instrumental support for daily living. Due to the necessity of immune 
suppression after alloHCT, individuals after transplant cannot be exposed to crowds, and 
must watch what they eat, drink, and touch while managing side effects and other 
physical complications (Beattie & Lebel, 2011). Therefore, instrumental support for daily 
living from lay caregivers is crucial, including driving, cooking, getting groceries, and 
fulfilling daily practical needs (n = 16/28, 57.1%).   
One participant mentioned,  
Fortunately, my father helps me out with the transportation most of the time, so I 
don’t have to rely on public transportation. So, I would be infection free or 




Another participant said that his wife makes sure to provide food and drink that are 
nutritious and hydrating, yet very enjoyable and creative.  
My wife was coming up with creative things, too. I started running out of ideas. 
She found things at Whole Foods like chicken potpie and roasted vegetable pot 
pie. I had a lot of stuff like that. It was very flavorful. (P10, age 48, male) 
 
His wife also provided him with different drinks to make sure he stayed hydrated. “I’m 
very aware of having to hydrate because of these drugs. It’s also part because of my wife. 
She buys creative food things for recipes and different drinks.” (P10, age 48, male).  
One participant suffered from stomach issues that made her nauseous, and her 
husband cooked food that was easy to swallow and digest. She said,  
Husband does all the homework. He cooks, I don’t. Doctor doesn’t want me to 
have outside food. We eat together, every 2-3 hours I have to eat, unless I have a 
stomach problem. It’s the time when I am going to eat. Some snack: rice cake, I 
am [Asian]. (…) Every 2 hours I ate rice cooked with lots of water. Don’t have to 
chew; I was able to eat just a little bit, every 2 hours. (P11, age 71, female)  
 
Instrumental support with financial matters. Hematopoietic cell transplant is 
expensive and requires an extensive treatment process over a long period of time, often 
creating financial hardship for individuals and their families after transplant (Khera et al., 
2014; Kim et al., 2015). Instrumental support with financial matters helped individuals to 
ameliorate their financial burdens, as well as their emotional stress and anxiety, as 
explicitly mentioned by some (n = 4/28, 14.3%). One mentioned, “I don’t even know 
where the bills are. I think he doesn’t want me to know because he doesn’t want me to 
worry.” (P07, age 55, female). Moreover, lay caregivers needed to balance the need for 
financial support with caring for individuals after transplant.  
She has her own business, but she works from home. Financially we weren’t 
fantastic but no, she didn’t work a lot. She was kind of holding it all together. 





Emotional support. Patients after alloHCT become physically and emotionally 
vulnerable (Rini et al., 2011). Therefore, emotional support, such as expressing 
encouragement, empathy and caring, plays a significant role in helping individuals after 
transplant. More than half of the participants reported receiving emotional support (n = 
11/28, 39.3%). “As soon as I went into the hospital, my husband put up a website for me 
because everyone called. So many people wrote in, it was wonderful.” (P07, age 55, 
female). Internet and technology development have also facilitated emotional support. “I 
stay home, but I’m not alone a lot. I do have friends who drop in a lot. We have a lot of 
support. And I Skype a lot, everybody has that all over the world.” (P07, age 55, female). 
For emotional support, individuals after transplant rely on a broader range of 
support sources than for instrumental support, including members of their extended 
family, friends, and acquaintances. In one case, an individual relied more on friends for 
emotional support than family members and distinguished the different types of support 
she received.  
They really support me in every way, my friends and my family. But for the 
medication, it’s my family, my husband and my little ones, they remind me all the 
time, but emotionally, my friends, they help me, like when I’m not feeling too up 
to it, or if I don’t have, like, enough energy they help me a lot. (P22, age 35, 
female) 
 
Individuals after transplant also perceive the importance of receiving emotional 
support. An individual after transplant suggested to other patients,  
To be able to talk about your problems, talk with friends and family. I would [be] 
trying to get them involved in a support group. I am lucky to have a very 
supportive family and friends, so I didn’t have to go out of my shell. You want 
people to ask how you are doing. You need someone who is patient enough to 




Informational support. Healthcare providers were the primary source of 
informational support, and consequently informational support was not sought from lay 
caregivers (n = 0, 0%). Lay caregivers helped as memory facilitators and conveyers of 
information from the healthcare providers. In one interview the caregiver interrupted to 
provide the correct response when the patient was asked what medications he had to take 
on an empty stomach. The wife interrupted that “the only one that he takes on an empty 
stomach is Prilosec.” (P25, age 66, male). This response indicates that she helped the 
patient to remember the information. One patient (n = 1/28, 3.6%) mentioned her 
“husband keeps asking doctors about [side effects of medications]” (P07, age 55, female). 
In this case, the patient’s husband helped the patient by clarifying and reiterating the 
information received from the doctors and also asked further questions that the patient 
might have missed or forgotten to ask. All other participants sought information either by 
using online resources or directly asking their healthcare providers. One person 
mentioned, “most of the teaching [is through] the doctors, and the nurses. And I also go 
online sometimes and do my little own research.” (P22, age 34, female).  
Mixed feelings about support. Some support was not helpful to some individuals 
(n = 7/28, 25 %). These patients showed ambivalence about the support they received 
from others. One participant chose not to share his situation with the people around him 
at all, believing that it would only cause more trouble.  
I’m a public figure, I kept it secret for a long time, (…) Keeping it secret: if I told 
them they were going to worry. They would want me to take medication they 
know about. Take this, take that. I [had] not wanted to deal with all that advice. 
Listen, I have my doctors. You guys, just pray, don’t try to be my doctors. (P19, 




Four patients expressed that they did not like the feeling of being monitored by 
their lay caregivers. They sought independence and control over their situation, though to 
no avail. In these cases, less support may be better. They perceived actions of support not 
as helpful, but somewhat unpleasant and even troublesome. An individual mentioned,  
My wife asks me all the time whether I’m taking medications, whether I took the 
medications, but basically I just think she’s asking too much because I’m just 
taking it. (P13, age 67, male)  
 
One mentioned that he does not take medications when he is bothered by other people 
(P17, age 50, male). The degree of support received, and the quality of relationships 
varied among individuals. 
In another case, the support from lay caregivers was ambiguously helpful. A 
participant mentioned the clothes she is accustomed to wearing.  
My sister doesn’t want me to use that, she buys new clothes. I want the old 
clothes. She said I cannot use it any more. Where is it what I like. Even [the 
clothes] is old [in] our thinking, I will go to the dry cleaning, wash and dry clean. 
I don’t know where the clothes are. She is hiding clothes away. I don’t know 
where they are. The attic is kind of high. (P29, age 62, female) 
 
Meaning in life. Some patients after transplant (n = 4/28, 14.3%) found new 
meaning in life, perceiving their life after transplant as another opportunity to love and be 
with loved ones. A participant mentioned,  
I have grown to love everything (…) I have taken advantage of time spent with 
my children, putting more attention to everything in life and being appreciative of 
God each and every day. (P23, age 59, female)  
 
Discussion 
This study explored the sources and functions of social support for adherence of 
individuals prescribed with multiple medications after alloHCT. They reported receiving 
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social support from both healthcare providers and lay caregivers in taking their multiple 
medications. Our findings suggest that these support sources serve complementary 
functions. While medical needs and informational support are mostly provided by 
healthcare providers, emotional and instrumental support is largely within the domain of 
lay caregivers. Thus, individuals must coordinate support-seeking from both healthcare 
providers and lay caregivers to support multiple medication intake and improve long-
term health outcomes and survival.  
Based on the findings, a model was developed to show the process of social 
support and summarize the results of the study (see Figure 3.2). The figure represents the 
interactions among support sources, including healthcare providers, lay caregivers and 
patients, and the functions of social support from each source. Based on a strong 
foundation of trust, healthcare providers are mainly responsible for providing 
professional informational support about prescribed medications and medical needs, and 
effectively communicating this information to patients and lay caregivers. Lay caregivers 
provide more intimate, daily instrumental support, such as providing transportation, 
refilling and organizing medications, cooking, doing grocery shopping, and other 
household chores. They are also the major sources of emotional support, encouraging and 
comforting patients with kind words, which helped patients to maintain a positive and 
optimistic attitude towards their recovery.  
The difficulties of recovery after transplant, often characterized by patients 
feeling unwell, fatigued, and socially limited due to their immunosuppressed state, make 
caregiver support essential for day-to-day living (Posluszny et al., 2018; Rini et al., 2011; 
So, Dodgson, & Tai, 2003; Wulff-Burchfield, Jagasia, & Savani, 2013). Although there 
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were some cases in which individuals found support somewhat unpleasant and 
ambiguous, individuals mostly described support acts as helpful. Our culturally diverse 
sample showed a uniformly high reliance on social support, although ethnicity and 
cultural background played a role in providing appropriate concrete supportive acts (e.g., 
support for adequate nutrition and hydration with buying bread and soft drinks vs. 
cooking rice with lots of water). Furthermore, caregivers’ presence often gave individuals 
after transplant reasons to live despite their difficult health conditions, supporting prior 
research (Krause, 2007). We assume that this mechanism is also true for lay caregivers 
themselves who were shouldering a high caregiver burden, meeting the considerable 
physical, financial, and emotional needs of individuals after transplant. The presence of 
their loved ones, despite their physical condition, may give meaning to their own lives 
and motivate them to overcome difficulties. 
The effort made by healthcare providers to increase trust in their patient 
relationships was deeply appreciated by participants. Patient-centered care is shown to be 
effective in improving health outcomes (Kelley, Kraft-Todd, Schapira, Kossowsky, & 
Riess, 2014; Rathert, Wyrwich, & Boren, 2013; Robinson, Callister, Berry, & Dearing, 
2008) and our findings reflect that. Although healthcare providers mainly provided 
informational support, they also made patients feel understood and cared for. This 
influenced patients’ communication with their healthcare providers, their attitudes 
towards them and to follow their instructions.   
This study makes contributions to the theory of social support for multiple 
medication adherence. Most adherence papers focus on methods for measuring adherence 
and how consistently an individual took medications. However, they do not highlight the 
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support patients require in their daily lives, particularly as a factor that influences 
medication adherence. By contrast, this study reveals the types of support that is needed 
for adherence to such a complex medication regimen with additional dietary and hygienic 
requirements. The multiple medication regimens in some cases required multiple 
caregivers to ensure adherence. For example, individuals after transplant need their lay 
caregivers’ help with transportation to attend doctor’s appointments (see Figure 3.2). This 
study is unique because it offers a detailed description of daily essential supportive 
actions for medication adherence.  
There are several limitations to the study. First, this study was conducted in a 
single treatment center in a large urban area, and the findings may not be generalized 
beyond this setting. Second, the treatment center we collaborated with requires 
nominating a dedicated support provider in order to receive an alloHCT, and the 
participants in the study all had access to health care. We were not able to study patients 
without such a support system to compare them with those who have a rigorous support 
system. However, during the study period, we received consent from two individuals 
after transplant whose lay caregiver support turned out to be very minimal, and both 
patients passed away before we could interview them. These two cases, in addition to our 
observations of the high support needs of our participants, indicate it is nearly impossible 
to maintain adherence to the multiple medication regimen and self-care recommendations 
without a rigorous support system, with severe consequences for survival. Third, there is 
a chance that individuals reported socially desirable responses during the interviews. 
However, some respondents attended or called in for interviews with their spouses or 
partners, who would correct them if they were giving responses that were not in line with 
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the caregivers’ perceptions. Moreover, participants were highly motivated and passionate 
about contributing to the study to improve care for future transplant recipients, so we 
believe that they gave us honest responses. 
Despite these limitations, the study has several strengths. First, participants in the 
study were from diverse ethnic and social backgrounds. Moreover, our participants were 
highly motivated to participate in the study and to learn about the study results. Some 
participants would contribute more than we asked (e.g., send pictures of their numerous 
pill containers). Some even requested a copy of the paper once it is published. Therefore, 
we can assume that many participants responded with earnestness and sincerity despite 
their illness. Furthermore, the findings of this study emphasize the importance of 
integrating social support into daily life. Social support plays a critical role in adherence 
to multiple medications. Finally, to facilitate adherence to this complex multiple 
medication and self-care regimen, all three parties—the transplant recipient, lay 
caregivers, and the healthcare providers—must work together as a team. A prior 
systematic literature review showed that social support from family members increases 
medication adherence (DiMatteo, 2004), but does not focus on healthcare providers. 
Based on our findings, support from healthcare providers is critical in medication 
adherence and medication adherence should be taken as a team responsibility.  
Adherence to multiple medications relies on a repeated process of actions, starting 
with attending appointments, refilling and organizing medications, preparing adequate 
intake of food and liquids, to correct and timely medication intake (see Figure 3.2). 
Social support from caregivers and healthcare providers is essential to enable adherence 
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in patients after alloHCT who are prescribed multiple medications and are often fatigued 
and unwell (Rini et al., 2011; Wulff-Burchfield et al., 2013).  
Based on our findings, we recommend the following practical measures to ensure 
adequate support for individuals after transplant. First, the initiation of a multiple 
medication regimen at home is a challenge. To ensure that patients and caregivers can 
follow the multiple medication regimen, healthcare providers need to devote time and 
attention to conveying all the details about the multiple medication regimen, including 
dietary and other treatment recommendations, to both patients and their caregivers. A 
scheduled dedicated prescription meeting delivered by a nurse or a pharmacist in the 
presence of both patient and caregiver was helpful to the participants in this study who 
received it. Methods to ensure adherence included a discussion of a printed medication 
list including the exact dose and time of intake, purpose and possible side effects; a 
supply of sufficient medications until the next appointment; provision of a pillbox to 
organize medications, color-coding of different medication bottles; and tips on how to 
remember medication doses (e.g., with cell phone reminders). Second, the requirement to 
nominate a dedicated lay caregiver after transplant seems to be warranted to ensure 
adherence to medical recommendations after transplant. Third, social support is essential 
for following a multiple medication regimen. If providers of social support cannot attend 
the prescription meetings, they should be informed about the patient’s support needs via a 




In conclusion, this study contributes to a more detailed theoretical and practical 
understanding of social support for a multiple medication regimen. To the best of our 
knowledge, this is the first in-depth investigation of multiple medication adherence and 
support in cancer patients. Moreover, the teamwork of patients, lay caregivers, and 
healthcare providers is the basis for adherence to a multiple medication regimen after 
transplant when patients are discharged home. Based on our findings, healthcare 
providers in health care settings and lay caregivers at home must work in tandem and are 
critical to promoting adherence to multiple medication regimens. The results of this study 
also suggest that there is a need to develop better organized patient education 
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STRATEGIES FOR STRENGTHENING ADHERENCE  
TO MULTIPLE MEDICATIONS 
Abstract 
Background: Although patients face significant challenges adhering to multiple 
medication regimens on a daily basis, the subject remains understudied. 
Objective:  The objective of this study was to explore adherence strategies developed 
and adopted by patients prescribed with multiple medications for an extended period of 
time using the Information-Motivation-Behavioral Skills (IMB) model.  
Methods: Semi-structured, in-depth interviews were conducted with 28 leukemia and 
lymphoma cancer patients (46.4% female, age: M = 53.97, 46.4% ethnic minority) who 
received an allogeneic hematopoietic cell transplant (alloHCT). Interviews covered 
different topics related to medication adherence, including questions on knowledge about 
the regimen, skills, and motivations. Interviews were transcribed, organized by themes, 
and coded using content analysis, with the IMB model (Fisher, Fisher, Amico, & Harman, 
2006) as a guiding theoretical framework.  
Results: Patients reported difficulties comprehending the information regarding their 
prescribed medications, although some patients knew the details of their regimens. 
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Patient interviews contained familiar themes of maintaining personal motivation 
(commonly having a positive attitude and beliefs about medications, and taking 
responsibility), receiving social support (commonly emotional and practical support from 
family members and friends, and support for medical needs from healthcare providers), 
and building behavioral skills relevant to taking medications (commonly having a fixed 
schedule and place, maintaining an adequate diet, and using prompts). However, there 
were also additional factors that have not been identified in the IMB model, like 
acceptance of patient role and general optimism. 
Conclusion: The study offers practical suggestions for improving adherence to multiple 
medications and also builds a foundation to develop an intervention specific to this 
population by eliciting individuals’ initial level of information, motivation, and 
behavioral skills regarding taking multiple medications. It also shows the need for 
mapping theoretical determinants of adherence and behavior change strategies for 
patients, lay caregivers, and health professionals to develop effective interventions to 
improve adherence to multiple medications.  
 





As life expectancy increases, more people are living with multiple chronic 
conditions that require a number of different medications (Buttorff, Ruder, & Bauman, 
2017; Kantor, Rehm, Haas, Chan, & Giovannucci, 2015; Kim & Parish, 2017; Sabaté, 
2003), making adherence to multiple medications an increasingly important issue in 
healthcare (Cross, Elliott, & George, 2016; Patton, Cadogan, et al., 2017; Wu & Green, 
2000). There has also been an increase in oral treatments for different health conditions, 
including cancer, and as patients and healthcare systems tend to prefer oral treatments, 
they are predicted to increase in the future (Banna et al., 2010; Mathes, Antoine, Pieper, 
& Eikermann, 2014; Ruddy, Mayer, & Partridge, 2009; Verbrugghe, Verhaeghe, 
Lauwaert, Beeckman, & Van Hecke, 2013). Consequently, patients assume a greater 
responsibility for their healthcare, as healthcare providers cannot directly supervise 
medication intake (Banna et al., 2010). However, medication adherence has been a 
struggle for many with chronic conditions, where only about half or less adhere (Sabaté, 
2003).  
Adherence to a multiple medication regimen is even more difficult than adherence 
to a single medication regimen (Claxton, Cramer, & Pierce, 2001; McDonald, Garg, & 
Haynes, 2002; Pantuzza, Ceccato, Silveira, Junqueira, & Reis, 2017). This holds true for 
patients after alloHCT, who are prescribed with multiple medications: the most recent 
observational study showed that more than half of the patients sampled poorly adhered to 
their medication regimens (Lehrer et al., 2018). A literature review found a wide range of 
adherence rates (33% to 95%) to multiple medications (Morrison, Martsolf, Wehrkamp, 
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Tehan, & Pai, 2017). An additional study in this patient group also found a range of 
adherence rates for different tasks required after alloHCT, including taking 
immunosuppressants and other medications, as well as maintaining hygiene and exercise, 
even with assistance from family caregivers (Posluszny et al., 2018). Moreover, previous 
studies on organ transplants also found that long-term adherence is a challenge for 
patients; the longer the treatment period after transplant, the less adherent patients were, 
underscoring the need for healthcare providers to continually (re)educate their patients 
(Bishop, Rodrigue, & Wingard, 2002; Morrison et al., 2017; Siegal & Greenstein, 1999; 
Teichman, Burker, Weiner, & Egan, 2000).  
Adherence interventions have had limited effectiveness, and vary greatly in terms 
of target patients, types, measures of adherence and health outcomes (Nieuwlaat et al., 
2014). As such, better interventions for adherence to multiple medications could be 
developed. A recent systematic review and meta-analysis of 771 trials concluded that 
medication adherence interventions should focus on behavioral strategies rather than 
cognitive strategies (influencing patients’ knowledge and beliefs) to improve adherence 
(Conn & Ruppar, 2017). Moreover, there is an unfortunate shortage of theory-based 
interventions for multiple medication adherence (Patton, Hughes, Cadogan, & Ryan, 
2017). The Information-Motivation-Behavioral Skills (IMB) model (Fisher, Fisher, 
Amico, & Harman, 2006), a behavioral theory, addresses the underlying mechanisms of 
adherence and focuses on information, motivation, and behavioral skills as determinants 
of adherence. The study of these determinants could help predict better adherence 
behavior and eventually produce better health outcomes (Fisher et al., 2006). This model 
has predominantly been used for HIV/AIDS treatment, but it has also been used for other 
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health conditions, such as diabetes and coronary artery diseases (Horvath, Smolenski, & 
Amico, 2014; Mayberry & Osborn, 2014; Zarani, Besharat, Sadeghian, & Sarami, 2010). 
Moreover, a review of 12 interventions based on the IMB model found that 10 of the 
interventions had significant behavior changes in different health conditions, indicating 
the promise of developing behavioral interventions using the IMB model (Chang, Choi, 
Kim, & Song, 2014). 
This study, using the IMB model, aims to provide a theory-based overview of the 
strategies patients prescribed with multiple medications have developed for themselves. 
This is the first step towards developing theory- and evidence-based interventions for 
multiple medication adherence (Bartholomew Eldredge et al., 2016). Also, this study uses 
a technique called elicitation research, in which we receive information from participants, 
where there are no right or wrong answers, and identify the specific needs of the group 
(Fisher & Fisher, 1992). The questions concerned medication adherence, motivations, 
and behavioral skills. According to Fisher & Fisher (1992),  
Interventions that are based on elicitation research to assess group-specific needs, 
sensitivities, and intervention tactics are more apt to be successful than those that 
are based on the investigators’ intuition because they are more apt to correspond 
to the needs and concerns of the target population. (p. 456). 
 
By eliciting information from participants, this study aims to contribute to the 
development of a more effective intervention.  
To study adherence strategies, we focus on individuals recovering from alloHCT 
(also known as bone marrow transplants) to treat leukemia or lymphoma. These 
individuals must adhere to a multiple medication regimen that is critical for their survival. 
Their multiple medication regimens typically include 18 medications with 24 or more 
pills per day in the first few months after transplant (Freifeld et al., 2011; Neumann, 
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Krause, Maschmeyer, Schiel, & von Lilienfeld-Toal, 2013; Tomblyn et al., 2009). When 
patients are discharged from the hospital, they need to incorporate multiple medications 
into their daily lives, a task many struggle with (Morrison et al., 2017; Posluszny et al., 
2018). Therefore, they are an appropriate population for studying multiple medication 
adherence.  
By parsing the myriad adherence strategies developed by alloHCT patients over 
the course of three to six months, this application of the IMB model sheds new light on 
the determinants of adherence to a multiple medication regimen. Only a handful of 
studies have examined the adherence of alloHCT patients, yielding varying adherence 
levels and illustrating the challenges of home care after transplant (Gresch et al., 2017; 
Morrison et al., 2017; Posluszny et al., 2018). But none has identified the specific 
strategies patients spontaneously developed to maintain their adherence. Although there 
have been previous studies on the determinants of medication adherence for cancer 
patients (Kardas, Lewek, & Matyjaszczyk, 2013; Patton, Cadogan, et al., 2017), to our 
knowledge, this is the first study that seeks to identify medication adherence strategies of 
alloHCT patients. Therefore, we seek to provide a list of practicable strategies for 
adherence to multiple medications.  
Methods  
This study was part of a larger transplant study of individuals with leukemia and 
lymphoma cancers. Using theory-based semi-structured in-depth interviews, the 
determinants (i.e. facilitators and barriers) of multiple medication adherence after 
transplant were identified using directed content analysis (Hsieh & Shannon, 2005). The 
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study was approved by the Institutional Review Board of all the related institutions, 
including Columbia University, Teachers College, and the hospital from which the data 
was collected. All participants provided written informed consent prior to participating. 
The study referred to the established standards for reporting qualitative results (Creswell, 
Klassen, Plano, & Smith, 2011; O’Brien, Harris, Beckman, Reed, & Cook, 2014; Tong, 
Flemming, McInnes, Oliver, & Craig, 2012; Tong, Sainsbury, & Craig, 2007), and 
especially followed COREQ (Tong et al., 2007) guideline (see Appendix C for more 
details). 
Setting and Participants 
Data were collected at a renowned hematology oncology department of a large 
urban area hospital. Individuals with leukemia and lymphoma cancers who received 
allogeneic bone marrow transplant HCT were asked if they were interested in 
participating in the study by their healthcare providers. Eligible participants included 
adults 18 years old or older, who spoke English, Spanish or Mandarin. Two interviews 
were in Spanish (7.1%), the rest in English (n = 26, 92.9%), and none in Mandarin. 
Participation was voluntary.  
Measures 
We chose a qualitative approach—theoretically-informed semi-structured in-
depth interviews—in order to give patients after alloHCT an opportunity to fully express 
their experiences and share the strategies they found most useful. A previous study on 
hypertensive patients successfully used a qualitative approach to explore the experiences 
of patients (Ogedegbe, Harrison, Robbins, Mancuso, & Allegrante, 2004). Moreover, 
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there is only one previous study that has examined the determinants of medication 
adherence for this particular patient group (Posluszny et al., 2018), so a qualitative 
approach, an elicitation research (as mentioned above), is sufficient to initiate the 
research and serve as a building block for developing an intervention (Creswell, 2013; 
Fisher & Fisher, 1992).  
The principal investigator, who is an expert in health psychology, developed the 
interview guide. The interview covered various topics on adherence and home care, 
including questions on general medication adherence, knowledge of medications, skills, 
social motivation and successful (or unsuccessful) adherence strategies (see Appendix A 
for the interview guide). Some examples of the questions include: “Please tell me about 
the medication(s) that you take. What medication does your physician currently 
prescribe?”; “Do you know which of your medications is an antibiotic/ 
immunosuppressant/ antifungal/ antiviral medication? How did you find this out?”; “How 
well do you think the medications work in helping people after transplant? Or do you 
think medications might harm people after transplant?”   
The inter-rater reliability for information (e.g. access to adequate information, 
lack of information, and flawed heuristics and implicit theory), motivation (e.g. positive 
attitudes, lack of positive attitudes, and social support from lay caregivers and from 
healthcare providers), and behavioral skills (e.g. strategies for dealing with difficult 
medications, fixed schedule, and diet) was calculated based on seven randomly selected 
interviews. We measured the similarity of coding between the two researchers using 
Cohen’s Kappa (κ), examining whether they agreed that a specific theme had been 
mentioned in a patient’s interview. The overall Kappa for information was initially 0.24, 
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leading the two researchers to discussed coding strategies. They reconciled the 
differences in the next round of coding, increasing the figure to 0.81. Kappa coefficients 
for motivation, including personal motivation (κ = 0.71), healthcare providers’ support (κ 
= 0.86), and lay caregivers’ support, were similarly high (κ = 0.86). The overall coding 
agreement for behavioral skills was initially 0.60, so the discrepancies were 
communicated between the coders, and when it was coded again, the agreement came out 
to be 1.00.  
Procedures 
Those who agreed to participate in the study were scheduled for an interview 
between 3 to 6 months after their first hospital discharge. In person (during hospital visits) 
or phone interviews were conducted depending on the schedule and health of the 
participant. In some cases, when participants were accompanied by their caregivers to the 
appointment, the caregivers joined the interviews as well. Two interviewers conducted 
each interview in order to facilitate a conversational experience: One person took notes 
and recorded the interview, and the other continued the dialogue. The semi-structured 
interview lasted from 40 minutes to an hour. Interviewers used a prepared and previously 
piloted interview script as a guide. Interviewers asked additional probing questions for 
more details. The interview guide was developed under the supervision of the principal 
investigator and modified after a few pilot studies.    
Interviews were audio recorded and transcribed later for analysis. All interviews 
were stored in a password secured drive and transcribed after the fact. For confidentiality, 
any identifying information was removed, and actual names were replaced by generic 




A codebook based on the Information-Motivation-Behavioral Skills model (Fisher 
et al., 2006) was developed prior to data analysis (see Appendix B). Themes were 
discussed and refined among the two researchers, and questions that could not be 
reconciled between them were discussed with the principal investigator. As outlined in 
the codebook, the interviews were coded according to the major themes of the 
Information-Motivation-Behavioral Skills Model using directed content analysis (Hsieh 
& Shannon, 2005). All interview transcripts were read repeatedly and manually coded by 
two coders using NVivo version 11. This software allows for the creation of categories 
and sub-categories, comparisons of coding by different researchers, and calculation of 
frequencies and discrepancies.  
Results 
Characteristics of Patients 
We collected interview data from 28 individuals (46.4% female, age: M = 53.97). 
Individuals in the study came from different ethnic backgrounds, including Non-Hispanic 
White (n = 15, 53.6%), African American (n = 2, 7.1%), Asian (n = 5, 17.9%), Hispanic 
(n = 5, 17.9%), and other (n = 1, 3.5%). Of these, 26 individuals answered all interview 
questions. The remaining two answered some of the interview questions but not all: 
Patients 20 and 21 could not complete the section on healthcare providers. Most of them 
interviewed in English (n = 26, 92.9%) and a few in Spanish (n = 2, 7.1%). 
Patients mentioned different strategies they had spontaneously developed for 
adherence to their medication regimens after transplant. Most themes that patients 
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mentioned neatly fell into the categories of the IMB model, but there were also themes 
that did not.  
Acceptance of Patient Role and General Optimism  
This theme did not neatly fit into the IMB model, but it is an important theme to 
note as a catalyst that allows for other adherence strategies. Many individuals in our 
sample (n = 13/28, 46.4%) approached their life after transplant with optimism, although 
they perceived changes to their quality of life after receiving the transplant and had fears 
and worries. Patients found hope in the fact that they were still alive, and that their health 
had improved. “We have to leave on a lighter note! The problems are almost over. You 
have to take the lighter side!” (P13, age 67, male). “Don’t take the treatment lightly, it is 
important. Remain positive above all” (P23, age 59, female).  
Moreover, some were able to find hope in the support they received from their 
close others and healthcare providers.  
So psychologically I am doing fairly well. (…) having a positive attitude was a 
big help. My family is very supportive. (…) So all in all I have no complaints. I’m 
happy to be alive (…) I keep everything in perspective. (P28, age 59, male)  
 
Another mentioned, “I’ve been so fortunate in so many ways in this process. It’s a 
terrible situation, but it’s been as good as it can go. It could be a lot worse.” (P10, age 49, 
male). There was also one patient, who found a strong faith and positive beliefs to be 
helpful in taking medications and recovering after transplant. She mentioned, “If you 
don’t believe, how can you be cured? And then always pray.” (P29, age 63, female).  
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Concerns, Fears, and Worries 
While many patients maintained their optimistic outlooks, others (n = 10, 35.7%) 
reported frustrations and anxieties, mainly due to uncertainties about their future, burdens 
on their families, health restrictions and side effects of treatment and medications.  
I had to get used to everything again, like eating. Also, it impacted my mental 
status. (…) I didn’t recognize my son, and I didn’t know where he lived. I didn’t 
know what was going on, and it was scary. It’s getting better now.” (P09, age 49, 
female) 
 
There were two cases where patients expressed frustrations about the consequences of 
their illness for family members. In one case, the patient had a daughter-in-law, who was 
pregnant. She had once lost her baby, and the patient was worried that she might lose her 
baby again, as she was “tense over things” (P38, age 64, female). In another case, every 
single family member struggled greatly after the patient became ill: his daughters 
struggled in school, and his wife became financially and mentally unstable (P10, age 49, 
male). The patient blamed himself for the plight of his family.  
Half of these 10 individuals (n = 5/10, 50.0%) reported mixed feelings of both 
optimism and fears during the interview. For example, one patient mentioned, “I don’t 
have cancer anymore. Because of the transplant and it makes everything better.” But he 
also mentioned, “[I felt] stress because I had to be in the hospital, and kids are in school 
and you really worry about what’s gonna happen next.” (P14, age 32, male).  
Information  
According to the IMB model, having adequate information about the medication 
is necessary for adherence. By contrast, flawed heuristics and implicit theories about 
medications usually led to making inappropriate decisions.  
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Information about medications. For information regarding their medications, 
patients referred to the personalized list provided by their healthcare providers during 
hospital discharge and clinical visits, which provides information about their prescribed 
medication, including their dosage, schedule, functions, and side effects. Most of them 
had a very long list of about 24 medications and a number of them (n = 9/28, 32.1%) had 
comprehensive knowledge of their medications. A patient, for instance, recalled his entire 
medication regimen.  
Around 7 o’clock in the morning I take Mepron and the Phenadone I think it’s 
called. Then at around 8 o’clock I would take the magnesium tablet, the Prograf 
and the Acyclovir. At 10 o’clock I’ll take the Voriconazole. At 2 o’clock I’ll take 
the magnesium tablet. At 6 o’clock I will take the Famotidine. 8 o’clock I would 
take the Prograf, the Tacrolimus, the Acyclovir and another magnesium tablet. 
And 10 o’clock I’d take the Voriconazole. (P28, age 59, male) 
 
However, a greater number of patients had partial knowledge of their medications 
(n = 19/28, 67.9%). “I know they gave me prednisone [which] is steroid, and they gave 
me voriconazole, acyclovir, the other one I don’t [remember].” (P32, age 46, female). 
Another mentioned,  
I have some pills that I take two times a day. I have another that I take once a day. 
I have another that I take three times a week, Monday, Wednesday and Friday. 
(…) oh the liquid medicine, that’s three times a day. (P23, age 59, female) 
 
Patients had difficulties comprehending and remembering their medication regimens due 
to the sheer number of medications and adjustments in their regimens.  
I’m not really sure. Not really sure, I mean there’s so many to keep track of. I’m 
just taking it cause I was told to. (…) But they’re lowering the immune-
suppressant. (P21, age 29, male) 
 
Another mentioned, “Immunosuppressants, I’m not sure. The antifungal I think is the 
uh…. let’s see. No I don’t know.” (P13, age 67, male).  
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There were a number of cases (n = 11/28, 39.3%) in which caregivers were 
heavily involved in refilling and organizing medications (see section on caregiver 
support). In some of these cases, the patient had little knowledge regarding the prescribed 
medications.  
All are pills, cannot tell... All are pills. You do not know an antivirus. Pills all 
come in a box and I only take the pills in that box. My daughters will fill the box 
of pills. (P12, age 54, female)  
 
Moreover, in two interviews, the spouses interrupted to provide additional information on 
medications: “Can I help him say it? I know them more than him.” (P20, age 50, male). 
Support from caregivers compensated for the patients’ lack of information, underscoring 
the benefits of adequately informing caregivers as well. Dedicated, well-informed 
caregivers can and sometimes must intervene if the patient cannot comprehend or retain 
information due to fatigue or cognitive problems.  
Flawed heuristics and implicit theories. Some individuals developed heuristics 
and implicit theories with questionable validity (n = 6/28, 21.4%). One individual 
reported, “I took [a] break from [the] medications on purpose because I was feeling 
better.” (P40, age 57, male). Another mentioned, “too much medications would build 
immunity and will not be as effective” (P20, age 50, male). Two individuals mentioned 
that they would never take medications without food because it would be harmful, 
although some of their medications were prescribed to be taken without food. These 
heuristics and implicit theories suggest the importance of holding programmatic 
discharge meetings in which the prescribed medication regimens, including their 




Personal motivation concerns individuals’ attitudes towards taking medications 
and their evaluation and beliefs about health outcomes (Fisher et al., 2006). This includes 
taking responsibilities for and perceiving the importance of taking medications, as well as 
maintaining positive attitudes and beliefs about medications and health outcomes.  
Taking responsibilities and perceiving the importance of taking medications. 
Our participants were highly motivated with a strong sense of commitment to and 
responsibility for their medication adherence. Almost everyone (n = 26/28, 92.9%) 
considered taking medications to be one’s own responsibility and prioritized taking 
medications. “Sometimes (…) I don’t want to take my medications. (…) I take them 
anyway, [laughs] I have no choice.” (P43, age 51, male). Another mentioned, 
I have to take all the medication every day, weekend and weekday does not matter. 
(…) I took it every time, no matter what. Taking medications is very important to 
get better. (P11, age 71, female) 
 
Positive attitudes and beliefs about medications and health outcomes. Many 
participants (n = 13/28, 46.4%) had positive attitudes and beliefs about medications.  
Some of them were not exactly very tasty and the repetition of taking all the 
medication all the time, but it’s a minor thing compared to all the benefits of the 
pills. I’m around today because I’ve been doing this! (P13, age 67, male) 
 
 However, quite a number of individuals (n = 9/28, 32.1%) also expressed concerns and 
ambivalent opinions about their medications due to their side effects, though they 
remained generally positive about their prescribed medications.  
I hope that the medications are helpful and effective for my recovery. The 
medication can be helpful in one way and hurtful in another way. (…) But I think 




Two participants were worried about the negative side effects after taking them: “I don’t 
want to take any more medications, every med has a side effect.” (P07, age 56, female). 
“I am concerned that the medicine may hurt my kidney, or my liver.” (P08, age 53, male).  
Social Motivation 
Social motivation refers to an individual’s perceived social support from others 
(Fisher et al., 2006). Healthcare providers are included in this domain, as well as family 
members and friends. Studies suggest that social support is a critical factor for post-
transplant care and adherence (Ehrlich et al., 2016) (To learn more about the specific 
association between social support and adherence to multiple medications, please refer to 
the second paper of the dissertation).  
Lay caregiver. All participants in our sample (n = 28/28, 100.0%) received some 
form of support from their family members and friends. The majority had a spouse or 
partner as a primary caregiver (n = 15/28, 53.6%), but many others received help from 
various family members and/or friends (n = 11/28, 39.3%), and others from non-family 
acquaintances (n=2, 7.1%).  
Instrumental support. Lay caregivers mostly provided instrumental support 
related to medication adherence (n = 26/28, 92.9%). “My wife does bulk of it (reminding 
to take medications). (…) She’ll ask me if I have and she’s the one that makes sure I’m 
taking my medicine.” (P26, age 50, male). Lay caregivers also helped patients with daily 
tasks (n = 16/28, 57.1%), such as cooking, completing house chores, shopping for 
groceries, and driving them to destinations. “My partner did the cooking, he works from 
home, he did all of that.” (P16, age 46, male). 
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Caregivers also supported patients financially (n = 4/28, 14.3%). Financial 
support was a critical and sensitive topic because some patients felt indebted to their 
partners and frustrated about their financial situation (n = 8/28, 28.6%). It was more 
salient among male patients, as 6 of 8 male patients mentioned financial struggles that 
came after treatment, as opposed to 2 out of 8 female patients. It is possible that men felt 
a stronger sense of financial obligation to their family and felt guilty or indebted for 
being supported by their partners.  
It’s been difficult financially. We have eaten into savings, into retirement. 
Because we were not producing income we needed it affected my wife’s business 
and my business. (P10, age 49, male)  
 
According to this participant, his wife was the sole income generator when he was in the 
hospital.   
Emotional support. Lay caregivers also provided emotional support (n = 11/28, 
39.3%). “With nobody, I could fall in depression and it would be a problem. Lonely. 
With support you do well.” (P07, age 56, female). “How spectacularly kind, gentle, 
loving people are caring for me.” (P41, age 65, female). Overall, lay caregivers can be 
encouraged to help individuals after transplant with medications by organizing and 
managing daily doses, picking up medication refills, and reminding patients to take 
medications. Lay caregivers are also crucial in helping patients complete daily tasks, such 
as cleaning and cooking, as well as providing financial support when needed. Moreover, 
sufficient emotional support can also motivate individuals to adhere to their regimens. 
Healthcare provider support. There were two patients coded as missing for this 
part of the interview because they did not feel well during the interview and requested to 
stop. The results on the subject of healthcare provider support are thus based on 26 
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interviews. Healthcare providers, mainly referring to doctors and nurses, worked closely 
together and were perceived as a team by most participants (n = 22/26, 84.6%). While 
doctors and nurses were the main healthcare providers, pharmacists and dieticians also 
helped, especially when patients had questions about their medications or diet.  
Informational support. Healthcare providers mainly provided patients with the 
appropriate information on the management of medications, as well as their functions and 
side effects (n = 23/26, 88.5%).  
Actually when I was getting discharged, they gave me list of medication and it’s 
self-explanatory and two people came from the pharmacy, they told me 
everything and also the nurse who discharged me and also [name of nurse 3] from 
here so I had a lot of people who really talked to me about the medication. (P22, 
age 35, female) 
 
Moreover, the healthcare providers informed patients about the appropriate diet and 
hydration (n = 6/26, 23.1%). “They gave me a chart of what I can eat and what I can’t eat 
and went through.” (P26, age 50, male). One patient complained about not receiving 
enough information at the discharge meeting and eventually being readmitted to the 
hospital. He claimed, “I ended up back in here (hospital). They didn’t talk about 
hydration.” (P01, age 65, male).  
Providing medical needs. Healthcare providers were responsible for patients’ 
medical needs, such as providing instructions about their medication intake (n = 18/26, 
69.2%). Patients were satisfied with the medical teams and their treatment. “He is a very 
good professional. (…) My doctor understood my needs and the communication was 
clear and important.” (P23, age 59, female). Another individual mentioned, “It was teams. 
Plural. They all helped. I couldn’t have asked for better care.” (P25, age 66, male).  
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Emotional support: Patients felt cared for, as well as encouraged and emotionally 
supported, by the healthcare providers (n = 9/26, 34.6%). “They are kind to me and help 
me.” (P11, age 71, female). Another individual mentioned,  
I think we (healthcare providers and self) have a good relationship. And they 
seem to really care. [W]hen I walked in after surviving that… ordeal during the 
summer, (…) they all started clapping and hugging me. It was nice. [Laughs] 
Made me happy to be there. Happy to be at the doctor’s. (P35, age 65, female)  
 
This emotional support not only motivated them, but it also made them feel more 
comfortable with the treatment. “Knowing that he is a good doctor, for me, has been very 
important. And everything has been made way easier.” (P23, age 59, female).   
Behavioral Skills 
Behavioral skills can help well-informed and motivated individuals adhere to their 
medication regimens. It includes different personal self-regulation strategies, such as 
following dietary recommendations, placing the pillbox at a fixed place, and taking them 
at a fixed schedule. There are also other strategies patients personally developed to aid 
their adherence.  
Fixed place. Participants mentioned different personal self-regulation strategies 
when organizing and managing their medication doses. First of all, almost all (n = 27/28, 
96.4%) participants mentioned they have a fixed place to take or organize their 
medications. There were three common places where individuals placed their 
medications—the kitchen (n = 9/27, 33.3%), especially the kitchen counter, bedroom (n = 
5/27, 18.5%) and living room (n = 3/27, 11.1%). Here are some examples: “Pillbox is in 
the kitchen (…) I (…) go to kitchen, take the first pill, then make coffee.” (P16, age 46, 
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male). “I typically keep the pillbox in the living room area.” (P39, age 68, male). “I have 
my medications in a visible place, on top of my bed.” (P17, age 50, male). 
Quite a few individuals kept medications in more than one place (n = 6/27, 
22.2%), such as in the bedroom and kitchen. One mentioned, “I usually take the 
medications in the kitchen table and living room.” (P11, age 71, female). There was a 
case, where the patient took medications in the bathroom (n = 1/28, 3.7%), and another 
case, where she kept medications where she worked (n = 1/28, 3.7%): “I tend to wait 
until I come to the studio (to take medications).” (P41, age 65, female). There were two 
cases (n = 2/28, 7.4%), where patients did not specify the room location and rather 
specified a spot, e.g. “on a dresser” (P13, age 67, male), “by the sofa” (P20, age 50, male). 
It is helpful for individuals to keep their medications in a location they frequent to 
develop the habit of taking their medications.  
Fixed schedule. Many individuals (n = 24/28, 85.7%) mentioned having a fixed 
schedule to manage and take their medications. “8 o’clock (AM), 10, 12 PM, 2, 8, 10 
(PM) whatever the time on the sheet says.” (P08, age 53, male). Some gave more specific 
schedules,  
8AM: Ursodiol and Magnesium. 2:00PM: Ursodiol and Magnesium. I take these 
two 3 times a day. After lunch – Mepron. If I cannot take it during the lunch hour 
I sometimes take it after dinner. 6-6:30 is two tablets. (Synthroid and Baraclude). 
7-7:30: Prozac. 8:00: Acyclovir, Ursodiol, Magnesium. 11PM: Levaquin. Before 
bed: another Prozac and Colace. (P11, age 71, female)  
 
There were individuals (n = 4/28, 14.3%), who were ambivalent in their responses 
and showed difficulties with having a fixed schedule.  
On a typical day I go by how I feel. Sometimes in the morning I have no energy. I 
go according to how I feel, I try not to abuse it by taking them all together, but 
sometimes I take them all together. It’s not uniform and according to schedule, 




If I sleep late I get all thrown off… if I sleep till 8 o’clock (…) I take my one pill 
that I’m supposed to take at 6 o’clock. And then I eat something and then I take 
the 5 or 6 pills that I’m supposed to take with food. Then I wait two hours to take 
the next pills. So I have specific times: 6, 8, 10, 8 and 10. But I haven’t really 
been following it. (P35, age 65, female) 
 
A patient particularly expressed difficulties with keeping a consistent schedule. “I’m 
actually having some trouble, based on my schedule. I just can’t have a consistency of 
taking my pills daily on a set time when I’m supposed to take it.” (P21, age 29, male). 
Although only one patient explicitly mentioned having trouble keeping a consistent 
schedule, the interviews suggest that others could also benefit from additional assistance 
taking their medications on time.  
Prompts, tools, and reminders. Except for two patients, all others (n = 26/28, 
92.9%) mentioned using different kinds of prompts, tools and reminders (including 
memory) to facilitate their medication adherence. About half of those who claimed to use 
prompts (n = 12/26, 46.2%) used objects, including a list of medications, phone alarm, 
time/clock and pillbox, as tools and prompts to take their medications on time.  
Well, I can manage on my own, I have the box sitting on the kitchen table, so it is 
right there that I don’t forget about it. So I’ve been doing this so long now, it is 
just automatic. (P31, age 44, female) 
 
For some (n = 6/26, 23.1%), taking medication became a routine, and even though they 
had a reminder, they remembered and did not have to depend on prompts: “Just basically 
the routine.” (P40, age 57, male). Two individuals (n = 2/26, 7.7%) had situational cues 
that reminded them of taking medications, which included meal times and other events on 
their daily schedules.  
Yeah, that’s like my little schedule so it kind of goes with eating the breakfast. 
Yeah, the one that I take after that is the breakfast. But definitely, after I finish 
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eating that will remind me that I have to take the rest of the medication. (P22, age 
35, female)  
 
Quite a few individuals (n = 6/26, 23.1%) combined different types of prompts, such as 
tools, memory, human reminders, and situational cues together.  
My children downloaded Dosecast on my iPad and programmed the medication 
on it (…) Every afternoon I take my sugar, text it to my husband, he wants to 
know everything, and he texts back. (…) Using the timer and the phone (…) I 
have a cellphone, (…) I have to have it with me all the time. My children [and my 
husband] scream and shout [if they do not hear from me]. (P07, age 56, female) 
 
There were only two patients (n = 2/28, 7.1%) who did not use any kind of prompts.  
There was also a case (n = 1/28, 3.6%), where the patient stopped using reminders 
or prompts after their regimen became simpler. “I was using my cell phone alarm for a 
while. I have a much more simplified currently, drug routine, so I stopped using alarms.” 
(P41, age 65, female). This shows how critical it is to have an alarm system or prompt to 
facilitate medication adherence until patients are prescribed with a simpler regimen or 
form an adherence routine. Some individuals mentioned being confused at times as to 
whether they took and/or refilled medications. There was also a case where the patient (n 
= 1/28, 3.6%) refilled the pillbox too frequently. It is advisable to keep a journal or diary 
in order to prevent cases similar to this. One individual in the sample used a diary to keep 
track of taking medications. “I keep a diary of when I wake up and take it.” (P01, age 66, 
male). This is something that can be recommended to individuals. It might be difficult for 
some individuals after transplant, but it might help others reduce the confusion as to 
whether they took or refilled their medications.  
Positive emotional self-reinforcement. Taking medications made very few 
participants (n = 3/28, 10.7%) feel better. This was not the main reason patients took 
medications on a regular basis, but it sometimes helped them to adhere. “Some 
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medications. Pain medication, because when pain goes away you feel a lot better.” (P14, 
age 32, male). “Not that I feel healthier but I feel content knowing that I took them.” (P43, 
age 51, female). “Simply that one shouldn’t give up so easily. That one should have more 
strength of character and of will and to continue on, nothing else.” (P23, age 59, female). 
Diet. Half of the patients experienced trouble eating due to a lack of appetite, 
smell and taste (n = 14/28, 50.0%). “The two main problems I have are the energy 
(fatigue) and no appetite, eating issues, I have to force myself to eat.” (P01, age 66, male). 
Moreover, they were under a restricted diet, including a low microbial diet (n = 12/28, 
42.9%), where certain foods were not allowed, including no raw foods, and everything 
had to be cooked thoroughly. They were also not allowed to have food from the outside 
(restaurants); instead, everything had to be cooked at home.  
I followed low microbial diet, no immunogenic food (…) I followed what they 
recommended, 95% of meals were home cooked. (…) [W]e went to restaurant 
that we knew (…) My partner did the cooking, he works from home, he did all of 
that (…) [the food was] pretty healthy and tasty. (P16, age 46, male) 
  
Therefore, they even experienced frustration eating and drinking.  
I drink a lot of water during the day. As much as I can, which is hard. (…)  I’m 
really not that hungry. A lot of times I eat even when I don’t feel like it because I 
know I have to. And a lot of things I’m not really happy with. I’d rather have 
something else but I can’t. (P39, age 68, male) 
 
Fortunately, appetite improved for some individuals after they resumed a regular diet. In 
our sample, several individuals (n = 7/28, 25.0%) had a regular diet and had no dietary 
restrictions. One mentioned,  
[I] didn't want to eat food, look at food, [or] smell food [during low microbial 
diet]. [I am] no longer on [low] microbial diet, but on regular diet to gain back the 




The role of caregivers was critical in terms of preparing nutritionally well-
balanced food based on the patients’ conditions. They had to consider many factors, 
including nutrition, taste, and ease of digestion. Moreover, culture also influenced their 
diet. “I’m from West Africa, you know I have to get my rice [laughs] (…) Rice, and I’ll 
have different kind of sauce.” (P22, age 35, female). Hydration was important regardless 
of dietary restrictions (low microbial or regular diet). Patients mostly drank water, 
Gatorade, lemonade and some fruit juices to stay hydrated. 
Utilization of healthcare resources. Individuals were able to adhere to their 
prescribed doses through the effective use of healthcare resources, including the 
pharmacy and hospital. This is an area where individuals’ behavioral skills work together 
with support from healthcare providers. Quite a number of individuals (n = 12/28, 42.9%) 
specifically mentioned how they utilized the healthcare resources available to them 
effectively. Most of them (n = 8/12, 66.7%) prepared and refilled medications ahead of 
time by using the hospital and pharmacy system (pick up or delivery). Individuals called 
in or visited the clinic and pharmacy to receive their refills on time. “I get my refills 
through the mail. It (refill) is not automatic. I phone it in.” (P26, age 50, male). But the 
pharmacists also called to make sure. “Thanks due to God, pharmacist has called, they 
call and remind me.” (P19, age 46, male).  
At the same time, a few individuals (n = 5/28, 17.9%) mentioned both good and 
bad experiences with their healthcare systems. For example, a few individuals found 
themselves in a situation where the pharmacy did not have the specific medication they 
needed. In one case, the patient could not purchase an extra supply of medication because 
of insurance issues (P20, age 50, male). Another mentioned,  
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Usually, the pharmacy, they remember. (…)  But this time maybe they got busy, 
they didn’t call me, so I was just going through the medication, both dapsone and 
acyclovir [were running out] one time. Just one time. (P22, age 35, female)  
 
One patient developed a habit of ordering ahead of time because the pharmacy once made 
her wait a week to obtain her medication. “From then on, I always order 2 weeks ahead” 
(P29, age 63, female).  
Moreover, there were a few individuals (n = 3/28, 10.7%), who experienced 
delivery problems and could not take their medications on time.  
The pharmacy claimed that they were going to deliver it, and then that the truck 
didn’t finish his rounds, and the next day the truck broke down (…) and instead of 
Tuesday I got it on Saturday. (…) That was the worst one that I skipped really a 
lot. (P13, age 67, male) 
 
 In most cases, however, the healthcare providers promptly took action before patients 
ran out of pills. To prepare for the worst cases where the medication refill is delayed, it is 
important that each patient checks with healthcare providers and restocks the medications 
ahead of time. 
Strategies to manage missed or late doses. Patients mentioned several reasons 
for missing or delaying a dose. The most frequently mentioned is forgetfulness; 
forgetting to take the medicine (n =21/28, 75.0%) or forgetting to refill (n =3/28, 10.7%). 
Other reasons include falling asleep/ sleeping through a dose (n = 9/28, 32.1%), being 
around other people (n = 2/28, 7.1%), being otherwise occupied (n = 7/28, 25.0%), and 
having difficulty managing changes in routines (n = 15/28 = 53.6%).  
Many individuals said they skip (n = 18/28 = 64.3%) the missed dose. “[If I forget 
to take a pill] I take it the next day. I do not take it late. I wait till next day.” (P09, age 49, 
female). Another mentioned, “[When I miss a dose] I skipped it and went on to the next.” 
(P26, age 50, male). One person also mentioned that depending on the importance of the 
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pill, the patient would decide whether to take it or not (P35, age 65, female). Patients also 
took the dose even a few hours later (n = 20/28, 71.4%). “Sometimes I forgot, then I take 
the pills an hour or two later than the scheduled time. When I am too busy then I forgot, 
mostly at work.” (P08, age 53, male). Two people (n = 2/28, 7.1%) mentioned adjusting 
the hours for the following doses: “The following doses I try to take them a little bit later.” 
(P14, age 32, male).  
Quite a number of individuals (n = 12/28, 42.9%) mentioned both skipping and 
taking the medications later. In one interview, the wife interrupted and said, “he (patient) 
takes it as soon as he remembers, or as soon as we can, or if it’s too close to the next dose, 
then we miss a dose.” (P25, age 66, male).  
It depends when I forget, if it’s an hour later, I take it. If it’s supposed to be taken 
at 12 in the afternoon and it’s now 9 at night, or it’s something once a day and I’m 
not taking any other medications I may take it or skip it for the day. But for the 
most part, I haven’t skipped too many. I do recall once or twice that I did skip a 
pill. (P13, age 67, male) 
 
Strategies not to miss a dose when being out/ traveling. A number of 
individuals (n = 12/28, 42.9%) mentioned they missed doses because they were out or 
traveling. In order to prevent missing doses when going out, one (n = 1/28, 3.6%) 
mentioned that she took the medications before going out (P11, age 71, female). The only 
time the individuals justifiably had to miss a dose was before the doctor’s appointment (n 
= 9/28, 32.1%): Patients would have to take an immunosuppressive drug, such as Prograf 
or Cyclosporine, after their blood was taken. Although there were cases in which 
individuals missed doses because they did not have enough pills in hand (n = 10/28, 
35.7%), many patients brought their medications with them as they went out (n = 24/28, 
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85.7%). “If I go to a friend’s (…) then I make sure I take the medication with me. Maybe 
occurs once or twice a month.” (P13, age 67, male).  
Strategies to deal with side effects. There were individuals who experienced 
difficulties in taking their medications due to side effects and sicknesses (n = 23/28, 
82.1%), like nausea, upset stomach, graft-versus-host diseases, and more. Not all 
individuals shared how they handled the side effects, but some did, including: taking 
another medication to relieve the effects of the medication in question (n = 5/28, 17.9%), 
eating and drinking something (n = 2/28, 7.1%), stop taking (n = 3/28, 10.7 %), cutting 
down the dose (n = 1/28, 3.6%), spacing out doses (n = 1/28, 3.6%), going to the 
bathroom (n = 1/28, 3.6%), using stockings for swollen legs (n = 1/28, 3.6%), and putting 
on lip balms for dry lips (n = 1/28, 3.6%). Here are some examples: “Stomach condition, 
eat small things, that is common sense, that is a good thing to do.” (P11, age 71, female). 
“I stop taking the medication (if I feel I am having side effects) and wait for the result by 
waiting. I’m being patient.” (P17, age 50, male). 
I was taking Zofran in the beginning, you take it once a day that keeps you from 
getting an upset stomach, I would take one hour before getting the shots and I 
never threw up ever. The one day I didn’t take it I was throwing up. But the 
Zofran constipates you. I learned the side effects, now if I take it one day I can’t 
take it the second day. (P01, age 66, male) 
 
A few individuals (n = 3/28, 10.7%) mentioned above used more than one strategy to 
deal with side effects. “Well I have the medicine [to deal with nausea] (…) I would just 
go into the bathroom and then you’re done, and you feel better.” (P31, age 44, female). 
Strategies for taking medications that are difficult to swallow. Patients had 
trouble swallowing some of the medications due to taste and size (n = 17/28, 60.7%). 
Many of them (n = 13/17, 76.5%) shared how they managed medications that are difficult 
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to swallow. Almost everyone (n = 12/13, 92.3%) mentioned they took their medications 
with food and/or drink. “They taste terrible, you have to drink more water and rinse it 
out.” (P07, age 56, female). 
Everything in the morning, with Gatorade Sub-zero (…) I can drink down 20 oz., 
it goes down so smooth (…)  I cannot do that with a glass of water. (P01, age 66, 
male)  
 
Sweet things, soda, Gatorade, milk help, put the pill all the way (…) When I tried 
with water, big pill when you cut at the end of the tongue it melts, hard to 
swallow. I tried with sweet drink it is working, keep trying with milk. (…) I don’t 
know exactly if (…) the medication or the empty stomach that makes the nausea, 
I cannot figure it out. (P11, age 71, female) 
 
Two patients used two strategies along with drinking water—closing their eyes or 
praying. “I closed my eyes and drink it and drink a lot of water.” (P22, age 35, female). 
Another mentioned, “I always take the medicine with water, swallow it and pray, that is 
all I am doing.” (P29, age 63, female). There was one person (n = 1/13, 7.7%), who held 
his breath to swallow the medications. “I hold my breath and then take it (medicine).” 
(P20, age 50, male).  
Discussion 
Individuals after transplant came up with numerous strategies for managing their 
multiple medications. In general, they maintained a positive attitude that underpinned the 
factors that the Information-Motivational-Behavioral Skills model (Fisher et al., 2006) 
delineates. We found that this framework is suitable for studying multiple medication 
adherence. Adequate information, personal and social motivation, and behavioral skills 
were central to maintaining adherence to multiple medication regimens. Many 
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participants experienced challenges but were able to initiate and maintain their complex 
regimens by developing personal strategies, as well as seeking help from others.  
Patients shared many of their lessons learned for taking multiple medications (see 
Table 4.1 for an overview). Patients reported that a positive attitude and optimism were 
helpful for adherence, so interventions should include strategies that affirm and 
encourage an optimistic attitude when faced with the challenge of multiple medications. 
Patients by and large were not able to remember the details of their regimen and relied on 
the printed information provided by their healthcare team. Therefore, interventions 
should ensure that healthcare providers offer patients adequate printed information when 
prescribing a multiple medication regimen, as well as include caregivers in explaining the 
multiple medications. The latter is essential because caregivers were frequently in charge 
of medication-related tasks. Taking multiple medications requires time and effort, and 
thus personal motivation. Patients reported taking personal responsibility (for example, 
treating it like a job) and adopting positive beliefs that each of the medications would 
lead to good health outcomes. Interventions could strengthen both responsibility-taking 
and positive beliefs. Social support, i.e., seeking emotional, instrumental, and 
informational support from close others and healthcare providers, was another important 
factor for maintaining multiple medication adherence, and caregivers were involved in all 
tasks, from medical appointments, refills, and reminders, as well as management of 
health insurances. Interventions should facilitate seeking and providing adequate support, 
as adherence tasks also multiply when patients need to manage multiple medications and 
health conditions. Patients with multiple medications needed to adjust their daily routines 
to adhere to the different intake times and instructions (e.g., on empty stomach, with vs. 
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without food). Therefore, they reported building a range of highly idiosyncratic 
behavioral skills to maintain optimal adherence and to manage late doses.  
This study is the first to investigate adherence strategies cancer patients with a 
multiple medication regimen developed spontaneously. These strategies can form the 
basis for developing adherence interventions for multiple medication intake. The findings 
suggest that the Information-Motivation-Behavioral Skills model is a useful framework 
for multiple medication regimens. We found room for improvement for each of the 
model’s adherence determinants in patients, who emphasized the role of caregivers that 
should therefore be included in adherence interventions for multiple medication intake. 
However, even with adequate information, motivation, and social support, patients and 
caregivers need to receive training in behavioral skills. For example, many patients 
reported using unreliable reminders, including visual cues such as leaving their pillbox on 
the kitchen table. But well-informed and motivated caregivers can remind patients or help 
them program reminders into their phones. Moreover, this study also suggested a 
modification to the IMB model by including general attitude and optimism. It is a new 
determinant that was not emphasized in the original IMB model, but this might be an 
especially significant factor for patients like those in our sample, who are required to 
manage treatment for a long period and are prescribed with multiple medications.  
Strengths of the study are myriad. This study provides concrete strategies that 
patients obtained from their difficult experiences post-transplant. It is very practical and 
can be applied with due caution, addressing concrete needs of individuals after transplant. 
Moreover, a qualitative approach allowed us to capture all individuals’ perspectives and 
their personal views on taking medications, as well as post-transplant treatment, making 
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the points more applicable and concrete to other patients. This is only the second study to 
examine different medication adherence tasks of individuals after transplant. The first one 
was released last year (Posluszny et al., 2018). Lastly, the findings suggest the feasibility 
and the promise of developing an effective intervention.  
Limitations  
It is unclear whether this study can be generalized to another group of individuals 
prescribed with a multiple medication regimen because we obtained data from one 
institution in an urban area, and we collected data from patients with a very specific 
health condition. Moreover, we had a relatively small sample size, though it was 
ethnically diverse and covered a wide range of age groups (20 to 60 and older). Some 
patients experienced trouble with cognitive functioning, so it is possible that they lost 
some of their memories (even those of recent events). We conducted in-depth interviews 
with patients, which are rich in narratives, but we were not able to apply a strict standard 
with which to determine whether patients were adherent or not. For future research, it 
would be interesting to collect caregiver interview data on the strategies patients 
developed during home care. It would also be interesting to study the perspectives of the 
caregivers, as they play such a crucial role.  
Conclusion 
Answering the call for focusing on behavioral strategies (Conn & Ruppar, 2017), 
we have found a number of strategies that patients developed spontaneously over time. 
Some strategies, such as receiving reminders from close others, seem to be suboptimal, 
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and could be supplemented with technological interventions, such as electronic reminders 
when the medication is not taken. Yet, the role of caregivers was significant in different 
areas of adherence, so caregivers must be included in training patients with adherence 
strategies. Moreover, some of the tasks can be divided and their responsibilities can be 
shared (Posluszny et al., 2018), so collaborative elements should be taken into 
consideration in developing the intervention. Patients took some time to develop these 
strategies. It would be ideal to train them on all adherence strategies on the prescription 
date to ensure adherence from Day 1. To this end, healthcare providers can ideally find 
ways to hold training sessions and prepare patients for discharge. Also, continually 
educating the patients over the course of the post-transplant treatment period seems 
important. Previous studies on organ transplants found that the longer the treatment 
period after transplant, the less adherent patients were, leading Bishop and colleagues to 
recommend educating patients repeatedly (Bishop, Rodrigue, & Wingard, 2002; Siegal & 
Greenstein, 1999; Teichman, Burker, Weiner, & Egan, 2000).   
Most studies on adherence to multiple medications focus on the elderly 
population because this group is more susceptible to illness and takes more medications 
(Cross et al., 2016; George, Elliott, & Stewart, 2008), but the focus should be broadened 
as a more recent study shows that younger patients with alloHCT had lower adherence 
than older patients (Lehrer et al., 2018). It might be difficult for the elderly population to 
adhere as they experience declines in cognitive and physical abilities with age, but 
younger individuals with severe health conditions may also experience the same or even 
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SUMMARY, IMPLICATIONS, AND RECOMMENDATIONS 
This dissertation sought to better understand the challenges patients face in 
managing multiple medications as part of a medical regiment following allogeneic 
hematopoietic cell transplant (alloHCT). The work consists of three related studies 
examining the feasibility of an electronic pillbox technology, the role of social support in 
facilitating adherence, and the psychosocial factors and strategies that enhance adherence 
for patients prescribed multiple medications after an allogeneic hematopoietic cell 
transplant. This chapter presents a summary of findings from each of the studies, 
discusses the implications of the work for theory and practice, and identifies both 
limitations and strengths and recommendations for future research. 
Feasibility of Using Electronic Pillboxes 
The first paper examined the feasibility of using an electronic pillbox for multiple 
medications. In line with previous studies of kidney transplant patients, which showed 
that the use of an electronic pillbox significantly improved medication adherence and 
supported the feasibility of using the technology (Davidson et al., 2015; McGillicuddy et 
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al., 2013), our study finds that it is feasible to use an electronic pillbox to facilitate 
multiple medication adherence. The paper’s main finding was the willingness of patients 
to use an electronic pillbox and the significant benefits they identified from doing so. For 
example, it provided storage for organizing medications and reminded patients to take 
and refill their doses. However, there were also several challenges to using the electronic 
pillbox, such as its limited portability and short battery life. Based on the 
recommendations from users, a more suitable electronic pillbox can be developed for 
individuals with multiple medications. Such a redesigned electronic pillbox could 
become the basis for a tailored, intensive longitudinal intervention for optimal adherence 
to multiple medications. This intervention would ideally not only be technology-based 
but also integrate social support for adherence as well. 
The Role of Social Support 
In the second paper, we examined the role of social support, specifically who 
helps patients after transplant and what kind of support patients receive given their very 
demanding self-care regimens and multiple medication regimens. In line with previous 
research, social support is a critical factor for adherence (DiMatteo, 2004). Both lay 
caregivers and healthcare providers provide ongoing support for patients after transplant. 
Patients predominantly mentioned doctors and nurses as healthcare providers giving 
support, but they also mentioned social workers, dieticians, and pharmacists. Lay 
caregivers were predominantly the patient’s partner/spouse, and more rarely other family 
members and friends. Healthcare providers were most helpful with patients’ medical 
needs and supplied information relevant to their medications and treatment. Although 
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emotional support from healthcare providers occurred only rarely, some patients were 
nevertheless emotionally touched and encouraged by their emotional support.  
Lay caregivers were the main source of emotional support for patients, using 
encouragement and empathy to address patients’ emotional needs. Patients also received 
ongoing instrumental support, i.e., tangible help with daily chores and taking/ refilling 
medications. Many lay caregivers were very involved in caring for patients after 
transplant, including some who took significant time off work. Moreover, high costs for 
medications and treatments led to a need for substantial financial support. Caregivers 
were involved with financing the healthcare costs and keeping the household together as 
the patients were unable to work. Guidelines for admitting patients for transplant 
prescribe that patients have a 24 hour/7-day a week lay caregiver. Our findings provide 
evidence that the needs of patients after transplant justify this requirement. Due to the 
high involvement of caregivers after discharge from hospital, they should be included in 
all patient education about the multiple medication regimen and self-care. In an ideal 
situation, healthcare providers, patients and lay caregivers work as a close-knit triad to 
ensure adherence to the complex medication regimen and recommended self-care. For 
example, during hospital discharge, patients appreciated that the clinic provided with 
each supply of medication a printed information form, which patients consulted regularly. 
However, in some cases patients did not have a dedicated caregiver who could attend the 
meetings together. Our findings suggest that a highly structured discharge meeting with 
the patient and caregiver present would reduce stress and could improve adherence to the 
multiple medication regimen after transplant. As we suggest in the paper, the discharge 
meeting needs to prepare the patients and the lay caregivers for the cascade of adherence-
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related tasks, not only medication intake. The cascade model (Figure 3.2) specifies the 
ways in which lay caregivers can help patients accomplish an array of tasks pertaining to 
adherence, including attending appointments, refilling and organizing medications, 
preparing food and liquid intake, and taking medications. For example, to support the 
attendance of doctor’s appointment, lay caregivers have to remind the patient of the 
appointment, provide transportation, and also accompany the patient to appointments. By 
doing so, the lay caregiver can receive at the discharge meeting all the relevant 
information necessary to support the patient in attending, refilling, preparing food and 
taking medications. Also, this discharge meeting should explain each medication’s 
benefits, doses, side effects, and possible drug interactions, and help patients organize all 
medications into a pillbox.  
Strategies to Manage Multiple Medications 
In the third paper, we found that patients develop different strategies to manage 
their multiple medications. Consistent with the Information Motivation and Behavioral 
Skills (IMB) model (Fisher, Fisher, Amico, & Harman, 2006), patients needed adequate 
information about their medications, personal motivation (positive attitude about 
medications), and social motivation (social support) from lay caregivers and healthcare 
providers. Moreover, patients needed different behavioral skills to help them adhere and 
overcome barriers to adherence. Most interestingly, this paper suggests some factors that 
have not yet been identified in the IMB model, which include the role of general 
optimism, worries, fear and concerns. The different lessons patients learned and 
developed for themselves in taking multiple medications are also shared in the paper.  
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Based on some of the findings of the third paper, one could infer why we found 
(in the first paper) the adherence rate to be about half (55%), which is within the range of 
the reported average adherence rate among individuals with chronic diseases in 
developed countries (Sabaté, 2003). Many (n = 19/28, 67.9%) reported that they did not 
have comprehensive knowledge of their numerous medications because it was too 
complicated to keep track of, and the regimens tended to change. Also, although many (n 
= 13/28, 46.4%) had positive beliefs about their medications, a number of people (n = 
9/28, 32.1%) expressed ambivalence and concerns about taking multiple medications and 
their side effects. Therefore, future interventions should carefully deliver detailed 
information about the prescribed medications, as well as emphasize their benefits.  
Implications for Theory 
Based on the findings of this study, the Information Motivation and Behavioral 
Skills model (Fisher et al., 2006) seems to be a suitable model for identifying factors of 
adherence to multiple medications. Having comprehensive information about 
medications and having positive motivations influence one’s behavioral skills. The 
patient interviews reflect the links between the three factors of the IMB model to 
adherence. The IMB model emphasizes the importance of support from caregivers and 
healthcare providers. However, it might be even more useful to further specify the 
sources of support and how they help, such as identifying different types of support. For 
example, when a patient is unable to absorb all of the pertinent information regarding the 
post-transplant regimen, the caregiver can receive the information alongside the patient 
and help the patient develop suitable skills as a follow up. For this to work, the same 
medical information must be conveyed to both the patient and caregiver.  
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Overall, this study underscores the need for a more systematic understanding of 
caregivers, particularly their role in enhancing adherence by influencing information, 
motivation, and behavioral skills available to patients. One suggestion is to integrate the 
IMB model with the social support cascade model for multiple medication adherence, as 
each of the adherence cascades—such as attendance of doctor’s appointment, refill and 
organization of medications, preparation for food and liquid intake, as well as taking of 
the medications—needs information, motivation, and skills. 
This study also identified factors not mentioned or under-specified in the model. 
The importance of trust in the relationship between patient and healthcare provider is not 
adequately treated in the IMB model. However, based on our findings, trusting and 
believing in healthcare providers’ decision-making in medical procedures influenced 
patients in their views and medication adherence. Moreover, meaning in life and 
spirituality, where individuals mentioned using prayers to maintain hope, were not 
identified in the model. They should be included as personal motivation factors, as 
general optimism and hope have been identified as important coping strategies for 
chronic diseases, including cancer (Duggleby et al., 2010; Raleigh, 1992).  
Implications for Practice 
There are several practical implications of the findings of these studies. First, 
some changes need to be made to the hospital discharge protocols. Both the patient and 
the caregivers need to be educated. For instance, the hospital needs to provide more 
comprehensive educational and practical training on medication adherence and other 




Second, instead of giving the electronic pillbox already filled by the nurses, 
giving patients a chance to practice refilling it would also help them further familiarize 
themselves with using the pillbox. It can be overwhelming for the patient and the 
caregivers to absorb all the information in one hospital discharge meeting, so having 
several meetings would be more helpful for them to master the information. Many relied 
on using the information sheet they were given at the hospital discharge. Creating a 
comprehensive and detailed information sheet would help. The hospital also needs to 
have a system in place to ensure that the said information sheet is always up-to-date. 
Most importantly, the same massage has to be delivered to the lay caregivers in order to 
equip them to help the patients.  
Third, in addition to delivering the technical matters related to medication 
adherence, such as gaining the information on their regimens, electronic pillbox and skills, 
sessions that can promote and help patients not to lose their hope might be needed. Hope 
seems to be a critical factor for the patients. Hospitals or healthcare centers can provide 
sessions on motivation and hope, which can encourage patients to stay optimistic, or 
create support groups so patients can encourage each other.  
Fourth, although this study specifically examined individuals after alloHCT, the 
findings can be applied to individuals with comorbid conditions who have to take 
multiple medications. This would especially include the elderly, a population that has 
increased drastically over time and is projected to continue its increase in the future 
(United Nations, Department of Economics and Social Affairs, & Population Division, 
2017). With advanced age, individuals are at increased risk for chronic diseases, and 
taking multiple medications represents a major challenge for this group (Nobili, Garattini, 
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& Mannucci, 2011; Pasina et al., 2014). Although the characteristics of individuals with 
leukemia or lymphoma after alloHCT do not exactly match those of other individuals 
with multimorbidity and an elderly individual, they face similar challenges. Thus, this 
study can offer practical suggestions for other populations where adherence to multiple 
medications is a problem.       
Limitations and Strengths 
The studies reported here present both limitations and strengths. First, the studies 
are based on a small study at a single cancer center in an urban area, so the findings may 
not be generalized to other conditions. In addition, this dissertation examined a very 
specific group of people who were in a difficult and life-or-death situation; they had no 
choice but taking the medications because otherwise they will die the next day. 
Adherence to multiple medications might look different in other patient populations and 
chronic conditions, who are in a less urgent situation. However, we assume that our 
findings that using an electronic pillbox is feasible, social support is required, and an 
array of adherence strategies is needed for ensuring adherence to multiple medications is 
likely to generalize to other populations who are prescribed multiple medications. A 
recent review of medication adherence interventions claims the need for improvement in 
interventions because the current state is that adherence interventions varied among 
different patient groups, treatments and health outcomes, and did not show significant 
improvement in clinical outcomes  (Nieuwlaat et al., 2014). The current dissertation laid 
the groundwork for developing a longitudinal intervention by way of elicitation research, 
identifying potentially critical determinants for a specific population undergoing long-
term treatment. This is a good starting point, as the sample, although small, was diverse 
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because of the location of the cancer center. Moreover, this group of patients had been 
understudied, and this is one of the first studies that examined this population.  
Second, the layout of the electronic pillbox, which promotes planning daily to 
weekly doses, might have influenced the nature of the purely observational study. 
Another limitation is that due to the nature of conducting an interview, there is a 
possibility that the patients have reported socially desirable responses.  
Third, while we examined the role of social support for medication adherence of 
individuals after alloHCT, the actual relationship between the adherence rate and social 
support was not examined. It is possible that those who reported receiving more social 
support had higher adherence rates and vice versa because of the complexity of the 
regimen and their health conditions. But the study focused on reporting what healthcare 
providers and close others did to help patients. It would be the logical next step to 
examine the relationship between social support and the level of adherence for 
individuals in the study. Finally, there may also be potential biases in analyzing the data, 
but we tried to maintain a common standard of objectivity with inter-rater reliability 
checks.  
Despite these limitations, the study had several notable strengths. First, this study 
is among the first to examine multiple medication adherence for patients after alloHCT. 
This is an understudied population, particularly in the context of multiple medication 
regimens. Based on the findings of this elicitation research, future interventions could be 
designed that address the needs of this specific population. Second, this study combines 
quantitative results of the electronic pillbox use with qualitative data. By combining an 
original metric of adherence with in-depth interviews, this study offers a systematic 
134 
	
examination of adherence while allowing patients to fully express and convey their 
opinions and feelings. Finally, this study directly speaks to the existing theoretical 
literature by adopting the IMB model. It also suggests novel categories to improve the 
model’s applicability, such as acceptance of patient role and general optimism.  
Recommendations for Future Research  
Based on the findings reported for these studies, several recommendations for 
future research are warranted.  First, more suitable electronic pillboxes for patients with 
multiple medications should be designed based on the information obtained from patients 
and tested for their feasibility and efficacy. An intervention specific to a particular group 
of patients, such as those who have undergone alloHCT procedures, can be developed 
using the findings of this elicitation research (Fisher & Fisher, 1992). Moreover, 
technology can be harnessed in different ways to advance interventions for adherence to 
multiple medications. For example, text messaging or smart phone applications could be 
used to notify, reinforce and monitor adherence (Lester et al., 2009). This would facilitate 
adherence and capture real-time data for research that could lead to further quality-of-life 
improvements. Integrating technology in adherence interventions is still a relatively new 
area, and it is premature to conclude whether it can improve adherence (Granger & 
Bosworth, 2011; Nieuwlaat et al., 2014); however, we need more investigations and well-
developed interventions. 
Not only does this project draw on the well-established IMB model for rigorously 
studying adherence, but it also uncovers additional determinants of adherence that can 
inform new interventions by allowing patients to freely provide their opinions, hopes, and 
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worries, as well as share some of the strategies they have developed for themselves. 
Future research should explore the relationship of these determinants to adherence and 
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Qualitative Interview Guide 
Multi-Method Study of Cancer Patients' Medication Adherence  
After Allogeneic HSCT 
Formative Research - In-Depth Interviews 
 
Interviewer Note:  
The goal of this interview is to get a description of the participants’ overall medication 
adherence behaviors, with a focus on obtaining (1) specific information on situational 
cues related to adherence, (2) daily preparatory action, facilitator use and opportune 
situations, and (3) barriers and barrier management strategies employed.  The interview 
also aims to elicit information on existing adherence strategies (i.e., specific plans for 
achieving adherence and anticipating barriers to it).  The key is to identify strategies 
already employed and to explore the feasibility of using new adherence strategies.  
Careful attention should be paid to obtaining information on both structural and daily (i.e., 
fluctuating) barriers and facilitators, as well as relationships between the two. 
 
Preparation:  
Study coordinator schedules interview with patient at patient’s convenience and hands 
out or emails interview material to patient (List of commonly prescribed medications for 
allogeneic HSCT patients). 
 
Script:   
Thank you for your time and for agreeing to participate in this project.  We are 
interviewing allogeneic HSCT patients to learn about their experiences taking 
medications after transplant. Your participation is very important to us.  
 
During the interview, my role is to learn about you and your experiences, feelings and 
behaviors related to taking your medications.  There will be plenty of opportunity for you 
to describe them in your own words. To better understand you, I may ask for more details 
and fuller descriptions about the things you say.  The focus of the interview will be on 
day-to-day barriers and facilitators to taking medication that you may experience. 
  
If you wish not to answer a question, simply say so and we’ll move on. If you wish to end 
the interview, let me know and we’ll do so immediately. This will not affect your 
receiving the incentive we offered to you. If you need rest for a little bit, please let me 
know and we can take a break. 
 
Everything you tell me will be completely confidential and will not be shared with anyone 
else outside the research team, including your healthcare providers. Your name will not 
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be used when anyone writes or speaks about the findings of the project and this interview. 
I may take some written notes as we talk in order for me to remember questions I want to 
ask you later. I will record the interview so that we can analyze later what was said. Do I 
have your permission to record this interview? 
Do you have any questions before we begin? 
 
PART 1: Background Information 
1. Please tell me a little bit about yourself.   
Probes: 
a. Where are you from? Where do you live? How long have you lived in [New York 
City]? 
b. How long have you been living with cancer?  
 
2. Can you share with me a little bit about how life has changed for you since your 
transplant? 
Probes: 
a. What is the best thing and worst thing that has happened since transplant? 
b. Has the transplant impacted your daily routines and/or behaviors?  How so? 
c. Do you ever feel like you have a hard time managing your cancer and the transplant 
treatment?  Can you tell me more about that? 
 
PART 2: Social Motivation and Support 
1. Who in your life knows that you are taking medication? (Probe for partners and other 
family members, friends known in person and online/Facebook friends, religious 
community, coworkers, roommates, etc.) 
a. Are there people in your life who support you taking your medications?  Are there 
people who do not support you taking your medication? 
b. Are there people in your life who help to make sure that you take your medication 
regularly/on time? 
c. Are there people in your life who make it difficult for you to make sure that you take 
your medication regularly/on time? 
 
 
PART 3: General Information about Medication Routines 
1. Please tell me about the medication(s) that you take.   
Probes: 
a. What medication does your physician currently prescribe? (Interviewer asks participant 
to look at a list of common medications with a picture, brand name, and substance name 
on it, so participant can list all)   
b. Do you know which of your medications is an 
antibiotic/immunosuppressant/antifungal/antiviral medication? How did you find this out? 
(e.g., from provider, participant looked it up, etc.) 
 




a. How many dosages do you take of your medication each day?  That is, how often do 
you take your medication, and how many pills do you have to take each time you take 
them? 
b. Do you have specific times to take your meds?  Do you have any specific places in 
which you normally take them? 
c. Are there moments of your day that represent good opportunities to take your 
medication?  Tell me about those moments.  What makes them good times to take your 
medication? How frequently/infrequently do you encounter them on a daily basis? 
d. Does the time or process you use for taking your medication change during the week 
(such as on weekdays compared to the weekend)? 
e. Which one(s) of your medications are you supposed to take with food?  Which one of 
your medications should you NOT take with food? 
f. Are you taking any other medications, herbal supplements, nonprescription 
medications, or recreational drugs aside from your medication?  When do you take those?  
g. Do you take them at the same time that you take your medication? 
Do you smoke? Have your smoking habits changed because you are taking medications? 
 
3. How often do you check for signs of infection? How often do you take your 
temperature? 
 
4. How has your physical activity changed since the transplant? For example, what 
physical activities such as walking, bike riding, going to the gym, do you do regularly 
since the transplant?  
 
PART 4: Behavioral Skills: Preparatory Actions/Using Facilitating Tools and 
Opportune Situations 
Now I would like to ask you about things that you may do to help you take your 
medication when you are supposed to.   
1. What do you do to help you take your medications? Do you place them in a visible 
place at home? Do you carry them with you? 
2. What tools do you use to help you take your medicine? (Probe for: reminders on cell 
phone, pill boxes, websites/online tools, cell phone tools/apps/websites, watches and 
alarm clocks, computer apps/email systems, etc.) 
Probes: 
a. What is the (exact) name of the application (if P specified a phone application)? 
b. Please describe how you use this tool. 
c. How is this tool working for you? 
d. How often/when do you use it? 
e. Since when have you used this tool?  
f. How did you find out about it? 
g. Have you tried any other tools or ways to remember to take your medication?  
h. What was your experience with those other tools? Why don’t you use them anymore? 
 
3. When and where do you prepare for using these tools? (e.g., set reminders every 
morning or evening, set alarm clock when I take a nap) 
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4. What do you do when you face a situation in which taking your medication is a 
challenge? (May need to probe with examples participant gave in part 3.) 
Probes: 
a. What do you do when you forget to take a pill? What about when you forget to take a 
pill 1-2 hours within the timeframe you were supposed to? 
b. How do you get back on track when you miss one or more dosages? 
 
5. Has your day-to-day life had to change because you are taking medication?  How so?  
Probe: 
a. What day-to-day changes have you had to make in order to facilitate taking your 
medication? 
 
6. How have your eating and drinking habits changed since the transplant? 
Probe: 
a. What changes have you made in order to facilitate eating and drinking during the day?  
b. What do you eat on a typical day – for breakfast? For lunch? For dinner? As snack? 
How often and how much do you eat? 
c. What do you drink on a typical day? Do you like some beverages better than others 
(for example tap water vs carbonated drinks?) How often and how much do you drink? 
Do you drink alcohol? How often and how much? What types of alcohol? 
d. Does feeling ill, such as nauseated, ever make it difficult to eat and/or drink during the 
day? How so? What have you done about it? 
 
PART 5: Barriers to Medication Adherence and Barrier Management 
1. How easy or difficult is it for you to take your medication when you are supposed to? 
Probes: 
a. How often do you miss a dose of your medications? (Daily, several times per week, 
once per week, once per month?) 
b. Are there reasons that you can think of why you might miss taking a dose of your 
medication?  Tell me more about that. 
c. Tell me about that last time that you forgot to take a dose of your medication.  What 
happened that time? 
d. Tell me about day-to-day issues that you may encounter that can affect whether or not 
you take your medication (on time or at all).  Are there certain times in your life when 
these issues arise more than other times? 
 
2. How have weight changes affected you taking your medication?  
Probe: 
a. Have changes in appetite made it difficult to take your medications when you are 
supposed to? 
b. Have you lost or gained weight since the transplant? How do you feel about this loss or 
gain of weight?  
 
3. I am going to ask you about specific situations you may have experienced in which 
taking your medication (on time or at all) was difficult or challenging.  Please tell me if 




a. Do you sometimes simply forget to take your medication? Why? (Busy with other 
things, sleeping through the dose)? What do you do about it? 
b. Do you sometimes remember that you should take your medication but you cannot do 
it because you do not have the pills at hand (e.g., left the pills at home)? What do you do 
about it? 
c. Do you sometimes forget to get your refill in time? (How do you get your refills?) 
What do you do about it? 
d. Do you have difficulty taking your medication on the weekends?  Why do you think 
this is so? What do you do about it? 
e. Do you have difficulty taking your medication when you or close others are traveling?  
Why do you think this is so? What do you do about it? 
f. Have you had difficulties when your daily routines changed (e.g., seasonal change, 
partner working longer hours)? What do you do about it? 
g. Are there certain moods or emotions that you experience that make it harder for you to 
take your medication? (E.g., do you sometimes forget to take your meds when you are 
sad or down?)  Can you tell me more about this?  Why/how do you think this happens? 
What do you do about it? 
h. Do you have difficulty taking your medication when you are with friends? Why is this 
so? What do you do about it? 
i. Do you have difficulty taking your medication when you are with people that do not 
know about your transplant?  Can you tell me more about that? What do you do about it? 
j. Is it hard for you to take your medication when you meet someone new or are out with 
people who don’t know you? What do you do about it? 
k. Do other medications make it difficult to take your medication?  What medications?  
How so? What do you do about it? 
l. Do you have difficulty taking your medication when you are drinking alcohol? How so?  
How often does this happen? What do you do about it? 
m. Do side effects impact taking your medication?  Which ones? What do you do about it? 
n. Does sickness impact you taking your medication?  How so? What do you do about it? 
o. Have you had trouble swallowing your medication and how does it taste? What do you 
do about it? 
p. Have you ever taking a break from your medication on purpose (e.g., to avoid side 
effects)? What do you do about it? 
q. Does a lack of money (i.e., end of a paycheck, periods of unemployment, a delayed 
government assistance check, lack of help from friends and family, etc.) ever make it 
difficult for you to take your medication? Can you tell me about this? What do you do 
about it? 
r. Does facing a hardship in your life make it difficult for you to take your medication?  
Why or why not? What do you do about it? 
 
4. Are there any other situations or times in which taking your medication is difficult or 
challenging for you that I haven’t described?  Please tell me about those situations/times 
and what you did. 
a. Which of the situations that affect you taking your medication are the ones that you 
experience most of the time? 
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b. Which situations in which taking your medication is difficult do you experience least? 
 
 
PART 6: Attitudes toward Healthcare Providers and Medications 
Now I would like to ask you some question about your experiences receiving health care. 
1. Tell me about your health care provider(s)?  
Probes: 
a. Who is the person who primarily treats you? 
b. What is your relationship like with your care provider?  Do you think your relationship 
with your care provider makes it easier or harder to take your medication?  How so? 
c. Do you feel like your care provider understands your needs?  [for minority patients: 
What about as a Black, Latino/Latina, Asian man/woman?]?  
 
2. What are your feelings about where your cancer came from? 
Probes: 
a. Do you feel that cancer is random or were there things that made you more vulnerable 
(lifestyle/smoking, stress)? 
b. Do you feel that the government and scientists are doing all that they can to treat 
people living with cancer?  Tell me more about that. 
 
3. Do you know how your medications work to keep you recovering? 
Probes: 
a. Do you believe that the medications are helpful/effective for your recovery? 
b. How well do you think the medications work in helping people after transplant?  What 
about in helping you specifically? 
c. Do you think medications might harm people after transplant? 
d. How important is it for you personally to continue to take your medications on a 
regular basis, without missing doses?  Why? 
e. How important do you think it is for transplant patients in general to take their 
medications on a regular basis, without missing doses? Why? 
 
4. How does taking your medications make you feel?  
Probes: 
a. Does it remind you of your disease status?   
b. Do you feel healthier when take your medication, as you might after eating a piece of 
fruit or taking a vitamin? 
c. Does the medications you take (or have taken) give you any side effects?  Tell me 
more about this.  What are the side effects?  Does/has having side effects make you not 
want to take your medication? 
 
 
PART 7: Electronic Pillbox  
I would like to know a little more about how you use the electronic pillbox. 
 




a. Was it a good experience? Bad experience? Why?  
b. Was it easy or hard to use the electronic pillbox?  
c. What do you like about the pillbox? What do you not like about the pillbox?)  
 
2. Did you have any problems using the electronic pillbox?  
Probe: 
a. How so? What did you do about the problems you encountered? 
b. Were you able to keep it plugged in all the time? Did you have to use an extension 
cord?  
c. Were there any other problems, for example, when you were traveling or leaving the 
home during the day? 
 
3. Where do you typically keep the pillbox?  
 
4. When do you typically refill the pillbox?  
 
5. Does anyone help you with the pillbox? Who, specifically, helps you use the pillbox? 
How do they help you?  
Probe: 
a. Do they help you refill the box? Do they help you get medications out of the box? 
 
6. Does anyone make it difficult for you to use the box? How so? What do you do about 
this? 
 
7. Would you find it helpful to have reminders such as text message alerts or alarms on 
the pillbox that would prompt you to take your medication? 
 
8. Is there anything else related to the pillbox that you would like to tell me? 
 
Thank you for your participation and for sharing your experiences with me today.  We 
are at the conclusion of the interview, is there anything else related to your experiences 




Interview Coding Guide 
Code Definition 
General guidelines and 
potential questions that 
target the code (but 
responses can be in 
















Questions along these lines: A 
lot of them are in PART 1: 
*What is the best thing and 
worst thing that has happened 
since transplant? *Has the 
transplant impacted your daily 
routines and/or behaviors?  
How so? 
(Note: Might be in other 
sections in the interview). 
“[I take] less than when I 
got discharged. It is going 
down, there is light at the 
end of the tunnel.” (P07, 
age 56, female).  
“So psychologically I am 
doing fairly well. (…) 
having a positive attitude 
was a big help. My family 
is very supportive. (…) So 
all in all I have no 
complaints. I’m happy to 
be alive (…) I keep 
everything in perspective.” 



























Questions along these lines: A 
lot of them are in PART 1: 
*What is the best thing and 
worst thing that has happened 
since transplant? 
*Feeling depressed or down? 
*Possible harm of 
medications? *Can you share 
with me a little bit about how 
life has changed for you since 
your transplant? 
(Note: Multiple codes might 
apply/ overlap with 
Depression, side effects). 
“I had to get used to 
everything again, like 
eating. Also, it impacted 
my mental status. (…) I 
didn’t recognize my son, 
and I didn’t know where he 
lived. I didn’t know what 
was going on, and it was 
scary. It’s getting better 
















































a & b.  
PART 3: General 
Information about 
Medication Routines 
1. Please tell me about the 
medication(s) that you take.  
a. What medication does your 
physician currently prescribe? 
(Interviewer asks participant 
to look at a list of common 
medications with a picture, 
brand name, and substance 
name on it, so participant can 
list all) 
b. Do you know which of 
your medications is an 
antibiotic/immunosuppressant
/antifungal/antiviral 
medication? How did you find 
this out? (e.g., from provider, 
participant looked it up, etc.)    
2. c. How many dosages do 
you take of your medication 
each day?  That is, how often 
do you take your medication, 
and how many pills do you 
have to take each time you 
take them? 
d. Do you have specific times 
to take your meds?  
g. Which one(s) of your 
medications are you supposed 
to take with food?  Which one 
of your medications should 
you NOT take with food? 
(Note: Any quotes on 
receiving information from 
health care providers or close 
others (informational support) 
should go into support 
section. The difference here is 
between possessing (adequate 
information) and receiving it 
(informational support)). 
“Around 7 o’clock in the 
morning I take Mepron and 
the Fenadine (to treat fever 
symptoms) Phenadone 
syrup for respiratory 
disease, allergic conditions, 
arthritis) I think it’s called. 
Then at around 8 o’clock I 
would take the um… 
magnesium tablet, the 
Prograf and the 
Acyclovir. At 10 o’clock 
I’ll take the Voriconazole. 
At 2 o’clock I’ll take the 
magnesium tablet. At 6 
o’clock I will take the 
Famotidine. 8 o’clock I 
would take the Prograf, the 
Tacrolimus, the Acyclovir 
and another magnesium 
tablet. And 10 o’clock I’d 
take the Voriconazole.” 
(P28, age 59, male).  
“Hopefully I can 
remember. Protozol that’s 
the immune-suppressant, 
and I’m taking Dapsone, 
Acyclovir, I’m also taking 
magnesium it’s a 
supplement. (…) I know 
Prograf that is so my body 
does not reject the bone 
marrow that I received 
from my little sister. And 
acyclovir that on is an anti-
virus. (…) And Dapsone, 
I’m not sure exactly but I 
think Dapsone is um, is to 
protect my lungs from 
pneumonia.” (P22, age 35, 











































a & b.  
Same questions as INF-
Adequate 
(Note: Same questions as 
INF-Adequate (but the patient 
response would be the 
opposite of INF-Adequate)). 
I: “Do all your medications 
make it difficult to take 
your prescribed 
medications?” P: “Probably 
yes but I don’t know. I 
don’t know specific timing 
or specific medicine. So I 
cannot give you definite 

























engage in a 
health 
behavior. 
No specific question that 
targets this category 
“I took [a] break from [the] 
medications on purpose 
because I was feeling 
better.” (P40, age 57, 
male). “too much 
medications would build 
immunity and will not be as 























Questions along these lines: 
*How important is it for you 
personally to continue to take 
your medications on a regular 
basis, without missing doses?  
Why? 
*How important do you think 
it is for transplant patients in 
general to take their 
medications on a regular 
basis, without missing doses? 
Why? *Do side effects impact 
taking your medication?  
Which ones? What do you do 
about it? *Does sickness 
impact you taking your 
medication?  How so? What 
do you do about it? 
(Responses with indication of 
perseverance, still taking the 
medications regardless the 
situation, taking medications 
is a priority, etc. would count 
as being responsible and 
prioritizing meds)  
“I have to take all the 
medication every day, 
weekend and weekday does 
not matter. (…) I took it 
every time, no matter what. 
Taking medications is very 
important to get better.” 
(P11, age 71, female).  
“Sometimes believe it or 
not I don’t want to take my 
medications. (…) I take 
them anyway, [laughs] I 
have no choice.” (P43, age 

















, that it will 
do good to 
treat.   
PART 6: Attitudes toward 
Health Care Providers and 
Medications 
Questions along these lines: 3. 
Do you know how your 
medications work to keep you 
recovering? a. Do you believe 
that the medications are 
helpful/effective for your 
recovery? b. How well do you 
think the medications work in 
helping people after 
transplant?  What about in 
helping you specifically? c. 
Do you think medications 
might harm people after 
transplant?  
4. How does taking your 
medications make you feel? b. 
Do you feel healthier when 
take your medication, as you 
might after eating a piece of 
fruit or taking a vitamin? (Did 
you feel or do you feel more 
healthy? When you took or 
when you keep making your 
medications? Do you believe 
that you progress each time 
you take your medications?) 
“The best thing that has 
happened is that I did not 
have that many side effects 
from the medications itself, 
but Some of them were not 
exactly very tasty and the 
repetition of taking all the 
medication all the time, but 
it’s a minor thing compared 
to all the benefits of the 
pills. I’m around today 
because I’ve been doing 






























PART 6: Attitudes toward 
Health Care Providers and 
Medications 
Questions along these lines, 
but the response would be the 
opposite: 3. Do you know 
how your medications work to 
keep you recovering? a. Do 
you believe that the 
medications are 
helpful/effective for your 
recovery? b. How well do you 
think the medications work in 
helping people after 
transplant?  What about in 
helping you specifically? c. 
Do you think medications 
might harm people after 
transplant? 4. How does 
taking your medications make 
you feel? b. Do you feel 
healthier when taking your 
medication, as you might after 
eating a piece of fruit or 
taking a vitamin? (Did you 
feel or do you feel more 
healthy? When you took or 
when you keep making your 
medications? Do you believe 
that you progress each time 
you take your medications?) 
(Note: Responses would be 
opposite from Per Mot- 
Positive attitudes and beliefs 
about meds and health 
outcomes). 
“I hope that the 
medications are helpful and 
effective for my recovery. 
The medication can be 
helpful in on way and 
hurtful in another way. (…) 
But I think they are doing 





























Healthcare provider related 
questions are the followings: 
1. Tell me about your health 
care provider(s)? Probes: a. 
Who is the person who 
primarily treats you? b. What 
is your relationship like with 
your care provider? Do you 
think your relationship with 
your care provider makes it 
easier or harder to take your 
medication?  How so? c. Do 
you feel like your care 
provider understands your 
needs?  [for minority patients: 
What about as a Black, 
Latino/Latina, Asian 
man/woman?]? 
“He is a very good 
professional. (…) My 
doctor understood my 
needs and the 
communication was clear 
and important.” (P23, age 
59, female) 
“It was teams. Plural. They 
all helped. I couldn’t have 
asked for better care.” 



























































ion.   
Part 2: Social Motivation and 
Support: 1. Who in your life 
knows that you are taking 
medication? (Probe for 
partners and other family 
members, friends known in 
person and online/Facebook 
friends, religious community, 
coworkers, roommates, etc.) 
a. Are there people in your 
life who support you taking 
your medications?  Are there 
people who do not support 
you taking your medication? 
b. Are there people in your 
life who help to make sure 
that you take your medication 
regularly/on time? 
“My wife does bulk of it 
(reminding to take 
medications). (…) She’ll 
ask me if I have and she’s 
the one that makes sure I’m 
taking my medicine.” (P26, 
age 50, male). 
“My partner did the 
cooking, he works from 
home, he did all of that.” 
























Part 2: Social Motivation and 
Support: 1. c. Are there 
people in your life who make 
it difficult for you to make 
sure that you take your 
medication regularly/on time? 
“It depends, they watch me. 
I’m under observation.” 
(P17, age 50, male). 
“Keeping it secret: if I told 
them they were going to 
worry. They would want 
me to take medication they 
know about. Take this, take 
that. I not wanted to deal 
with all that advice. Listen, 
I have my doctors. You 
guys, just pray, don’t try to 
be my doctors. This remedy 
comes from the family. 
They send me home 
remedies. Well, they didn’t 
listen. Their kindness 






















In Part 6: Attitudes toward 
Health Care Providers and 
Medications & some 
questions throughout the 
interview regarding 
medications  
“What I discovered is they 
don’t do enough here 
telling people how to work 
out.” (P01, age 66, male).  
“First time, no, nurses did 
discharge from hospital 
with filled box, the nurse 
did not show, we had to 
figure it out ourselves.” 









pills at a 
specific 
place 
Part 3: General Information 
about Medication Routines: 2. 
Please tell me when and 
where you usually take your 
medications on a typical day? 
c. How many dosages do you 
take of your medication each 
day?  That is, how often do 
you take your medication, and 
how many pills do you have 
to take each time you take 
them? d. second part of the 
question: Do you have any 
specific places in which you 
normally take them? Part 4: 
Behavioral Skills: Preparatory 
Actions/Using Facilitating 
Tools and Opportune 
Situations: 1. What do you do 
to help you take your 
medications? Do you place 
them in a visible place at 
home?  
“Pillbox is in the kitchen 
(…) It is where I make 
coffee in the morning. (…) 
I (…) go to kitchen, take 
the first pill, then make 
coffee.” (P16, age 46, 
male). “I typically keep the 
pillbox in the living room 
area” (P39, age 68, male). 
“I have my medications in 
a visible place, on top of 
























Part 3: General Information 
about Medication Routines: 2. 
Please tell me when and 
where you usually take your 
medications on a typical day? 
d. first part of the question: 
Do you have specific times 
to take your meds? 
Also includes questions like: 
are there moments of your 
day that represent good 
opportunities to take your 
medication? And how 
frequently or how 
infrequently do you encounter 
these good opportunities on a 
daily baseis Does the time or 
process you use for taking 
your medication change 
during the week? Do you 
have difficulty taking your 
medication on the weekends? 
Why do you think this is so? 
What do you do about it? 
“8 o’clock, 10, 12 PM, 2, 8, 
10 whatever the time on the 
sheet says.” (P08, age 53, 
male).  
“8AM: Ursodiol and 
Magnesium. 2:00PM: 
Ursodiol and Magnesium. I 
take these two 3 times a 
day. After lunch – Mepron. 
If I cannot take it during 
the lunch hour I sometimes 
take it after dinner. 6-6:30 
is two tablets. (Synthroid 
and Veracru). 7-7:30: 
Cryozac. 8:00: Acrovia, 
Ursodiol, Magnesium. 
11PM: Levaquin. Before 
bed: another prylozac and 
Colase. Sometimes, once or 
twice is Quodimethol.” 



















on that day/ 
at the 
moment) 
Same questions as Skills- 
Fixed schedule but the 
response would be the 
opposite  
(Note: Sometimes responses 
include INF-flawed heuristics 
and implicit theories).  
“On a typical day I go by 
how I feel. Sometimes in 
the morning I have no 
energy. I go according to 
how I feel, I try not to 
abuse it by taking them all 
together, but sometimes I 
take them all together. it’s 
not uniform and according 
to schedule, but by night I 
take everything.” (P17, age 
50, male).  
“I’m actually having some 
trouble, based on my 
schedule. I just can’t have a 
consistency of taking my 
pills daily on a set time 
when I’m suppose to take 




































, such as 
meal times.  
Part 4: Behavioral Skills: 
Preparatory Actions/Using 
Facilitating Tools and 
Opportune Situations: 2. What 
tools do you use to help you 
take your medicine? (Probe 
for: reminders on cell phone, 
pill boxes, ziplock bags, 
websites/online tools, cell 
phone tools/apps/websites, 
watches and alarm clocks, 
computer apps/email systems, 
etc.)  
“Well, I can manage on my 
own, I have the box sitting 
on the kitchen table so it is 
right there that I don’t 
forget about it. So I’ve 
been doing this so long 
now, it is just automatic.” 
(P31, age 44, female) 
“Yeah, that’s like my little 
schedule so it kind of goes 
with eating the breakfast. 
Yeah, the one that I take 
after that is the breakfast. 
But definitely, after I finish 
eating that will remind me 
that I have to take the rest 
of the medication.” (P22, 
























. Not using 
any kinds of 
reminders.  
Same questions/ sections as 
Skills- Prompts, tools & 
reminders but patient 
responses would be using 
memory/ making mental 
notes, and/or not using any 
prompts/ tools/ reminders. 
“I don’t use any tools.” 
(P09, age 49, 
female). “I don’t. Just 
memory. It feels less 
important or serious now so 
it’s not at the top of my 
mind. Before I was like I 
need to take these drugs 
today. I was fearful because 
I thought if I don’t take 
this, I’ll have a reaction. 
But now it doesn’t feel that 
way. I’ve read up on what 
it does- it’s good 
preventative bacteria but it 
never felt all that serious.” 

































(pick up or 
delivery). 
Individuals 
have to call 
in to receive 
refill on 
time. 
Questions like: *Do you 
sometimes forget to get your 
refill in time? (How do you 
get your refills?) What do you 
do about it? OR *Are there 
people in your life who 
support you taking your 
medications?  Are there 
people who do not support 
you taking your medication? 
Are there people in your life 
who help to make sure that 
you take your medication 
regularly/on time? 
“I get my refills through the 
mail. It (refill) is not 
automatic. I phone it in.” 
(P026, age 50, male). 
However, there were cases 
where the pharmacist called 
to make sure. “Thanks due 
to God, pharmacist has 
called, they call and remind 

























Questions along these lines: 
*Do you sometimes want to 
take your medication but 
cannot because you don’t 
have the pills at hand? *Do 
you sometimes forget to get 
your refill on time? *How 
often do you miss a dose of 
your medications? (Daily, 
several times per week, once 
per week, once per month?) 
*Are there reasons that you 
can think of why you might 
miss taking a dose of your 
medication? Tell me more 
about that. *Which of the 
situations that affect you 
taking your medication are the 
ones that you experience most 
of the time?  
“Well the pharmacy…gave 
me a certain number of 
pills because of insurance. 
So they give you just 
enough…but it’s not really 
like you know, extra. So 
that’s the situation.” (P20, 
age 50, male) 
“Yeah but um that was 
acyclovir and dapsone [that 
I missed a couple of times]. 
Usually, the pharmacy, 
they remember. I guess 
they got busy. They will 
actually refill the 
medication and call me. I 
think I got used to that. 
Yeah, they refill and they 
will call me and even if 
there was nobody home, 
they do leave a message. 
But this time maybe they 
got busy, they didn’t call 
me, so I was just going 
through the medication, 
both dapsone and acyclovir 
one time. Just one time.” 
(P22, age 35, female).  
“The pharmacy claimed 
that they were going to 
deliver it, and then that the 
truck didn’t finish his 
rounds, and the next day 
the truck broke down (…) 
and instead of Tuesday I 
got it on Saturday. (…) 
That was the worst one that 
I skipped really a lot.” 

















with lack of 
appetite. 
Questions from PART 4: 
Behavioral Skills: Preparatory 
Actions/Using Facilitating 
Tools and Opportune 
Situations: *How have your 
eating and drinking habits 
changed since the transplant? 
a. What changes have you 
made in order to facilitate 
eating and drinking during the 
day? b. What do you eat on a 
typical day – for breakfast? 
For lunch? For dinner? As 
snack? How often and how 
much do you eat? c. What do 
you drink on a typical day? 
Do you like some beverages 
better than others (for 
example tap water vs 
carbonated drinks?) How 
often and how much do you 
drink? Do you drink alcohol? 
How often and how much? 
What types of alcohol? d. 
Does feeling ill, such as 
nauseated, ever make it 
difficult to eat and/or drink 
during the day? How so? 
What have you done about it? 
*How is your appetite? 
“I followed low microbial 
diet, no immunogenic food 
(…) I followed what they 
recommended, 95% of 
meals were home cooked. 
(…) We went to restaurant 
that we knew (…) My 
partner did the cooking, he 
works from home, he did 
all of that (…) [the food 
was] pretty healthy and 























Questions from PART 5: 
Barriers to Medication 
Adherence and Barrier 
Management: How have 
weight changes affected you 
taking your medication? a. 
Have changes in appetite 
made it difficult to take your 
medications when you are 
supposed to? b. Have you lost 
or gained weight since the 
transplant? How do you feel 
about this loss or gain of 
weight?  
“The two main problems I 
have are the energy 
(fatigue) and no appetite, 
eating issues, I have to 
force myself to eat.” (P01, 
age 66, male). “I drink a lot 
of water during the day. As 
much as I can, which is 
hard. (…)  I’m really not 
that hungry. A lot of times I 
eat even when I don’t feel 
like it because I know I 
have to. And a lot of things 
I’m not really happy with. 
I’d rather have something 
else but I can’t.” (P39, age 



























PART 5: Barriers to 
Medication Adherence and 
Barrier Management: I am 
going to ask you about 
specific situations you may 
have experienced in which 
taking your medication (on 
time or at all) was difficult or 
challenging. Please tell me if 
you have experienced this 
situation and if so, what you 
did about it. *Do you have 
difficulty taking your 
medication when you or close 
others are traveling?  Why do 
you think this is so? What do 
you do about it? 
“If I go to a friend’s (…) 
then I make sure I take the 
medication with me. 
Maybe occurs once or 
twice a month.” (P13, age 











they did not 




Questions like: PART 5: 
Barriers to Medication 
Adherence and Barrier 
Management: I am going to 
ask you about specific 
situations you may have 
experienced in which taking 
your medication (on time or at 
all) was difficult or 
challenging. Please tell me if 
you have experienced this 
situation and if so, what you 
did about it.  *How often do 
you miss a dose of your 
medications? (Daily, several 
times per week, once per 
week, once per month?) *Do 
you sometimes want to take 
your medication but cannot 
because you don’t have the 
pills at hand? 
“Once or twice a month. 
Because that would be 
because I got stuck in 
traffic or I ended up 
spending the night some 
place and I didn’t have my 
medication with me.” (P14, 






















even a few 
hours later 
(1-2 hours).  
Questions from PART 4: 
Behavioral Skills: Preparatory 
Actions/Using Facilitating 
Tools and Opportune 
Situations: What do you do 
when you face a situation in 
which taking your medication 
is a challenge? (May need to 
probe with examples 
participant gave in part 3.)  
a. What do you do when you 
forget to take a pill? What 
about when you forget to take 
a pill 1-2 hours within the 
timeframe you were supposed 
to? 
b. How do you get back on 
track when you miss one or 
more dosages? 
“(when I miss a dose) I 
skipped it and went on to 
the next.” (P26, age 50, 
male).  
“(If I forget to take a pill) I 
take it the next day. I do 
not take it late. I wait till 
next day.” (P09, age 49, 
female).  
“[I]t depends when I forget, 
if it’s an hour later, I take 
it. If its supposed to be 
taken at 12 in the afternoon 
and it’s now 9 at night, or 
its something once a day 
and I’m not taking any 
other medications I may 
take it, or skip it for the 
day. But for the most part, I 
haven’t skipped too many. I 
do recall once or twice that 
I did skip a pill.” (P13, age 
67, male).  
“Sometimes I forgot, then I 
take the pills an hour or 
two later than the 
scheduled time. When I am 
too busy then I forgot, 























PART 5: Barriers to 
Medication Adherence and 
Barrier Management: I am 
going to ask you about 
specific situations you may 
have experienced in which 
taking your medication (on 
time or at all) was difficult or 
challenging.  Please tell me if 
you have experienced this 
situation and if so, what you 
did about it. *Do you 
sometimes forget to take your 
medication on time? 
“I forgot. Maybe stick-ems 
all over the place. Last time 
you forgot, last week. I 
took my night pills, 
morning pills were still 
there. Once it happens I 
become more cognizant.” 
(P01, age 66, male)  
“I: Do you sometimes 
remember to take your 
medication, but can’t do so 
because you do not have 
any of them? P: Well, yeah, 
of course it [pills] wasn’t 
with me, I’ll remember 
sometimes if I’m at—oh, I 
forgot it, that’s…” (P38, 
age 64, female) “It’s been a 
few times when I was uh 
late on getting refills. Not 
late but calling in. I always 
get them on time.” (P39, 
age 68, male). “When I 
forgot to take one pill, it 
was prozac. That day I 
went to bed a little earlier. I 
was going to take a rest but 
I slept through the night. 
When I woke up in the 
morning I found that I 
missed one.” (P11, age 71, 
female). “More than often 
it would be the sleeping 
over the time that you are 
supposed to be taken.” 











































PART 4: Does feeling ill, 
such as nauseated, ever make 
it difficult to eat and/or drink 
during the day? How so? 
What have you done about it? 
PART 5: Barriers to 
Medication Adherence and 
Barrier Management: *Do 
side effects impact taking 
your medication?  Which 
ones? What do you do about 
it? *Does sickness impact you 
taking your medication?  How 
so? What do you do about it? 
“I stop taking the 
medication (if I feel I am 
having side effects) and 
wait for the result by 
waiting. I’m being patient.” 























side effects.  
PART 4: Does feeling ill, 
such as nauseated, ever make 
it difficult to eat and/or drink 
during the day? How so? 
What have you done about it? 
PART 5: Barriers to 
Medication Adherence and 
Barrier Management: *Do 
side effects impact taking 
your medication?  Which 
ones? What do you do about 
it? *Does sickness impact you 
taking your medication?  How 
so? What do you do about it? 
I: “The medicine you take 
(or have taken) gives any 
side effects? Tell me more 
about this. What are the 
side effects? The side 
effects have made him not 
want to take your 
medication?” P: “No pills 
cause me nausea or 
dizziness or any of these 
hoes. No side effects.” 
(P12, age 53, female).  
I: “Does the medications 
you take (or have taken) 
give you any side effects?  
Tell me more about this.  
What are the side effects?  
Does/has having side 
effects make you not want 
to take your medication?” 
P: “Yeah, there’s one 
fungus medication that I 
have to take at a different 
time from the Prograf. 
That’s the only one.” (P07, 























with food to 
reduce the 











PART 5: Barriers to 
Medication Adherence and 
Barrier Management: Please 
tell me if you have 
experienced this situation and 
if so, what you did about it. 
Have you had trouble 
swallowing your medication 
and how does it taste? What 
do you do about it? 
(Note: Can combine different 
strategies (more than one) to 
deal with difficult 
medications). 
“Everything in the 
morning, with Gatorade 
Sub-zero (…) I can drink 
down 20 oz., it goes down 
so smooth (…)  I cannot do 
that with a glass of water.” 
(P01, age 66, male). “They 
taste terrible, you have to 
drink more water and rinse 
it out.” (P07, age 56, 
female). “Sweet things, 
soda, Gatorade, milk help, 
put the pill all the way (…) 
When I tried with water, 
big pill when you cut at the 
end of the tongue it melt, 
hard to swallow. I tried 
with sweet drink it is 
working, keep trying with 
milk. (…) I don’t know 
exactly if (…) the 
medication or the empty 
stomach that makes the 
nausea, I cannot figure it 
out.” (P011, age 71, 
female).  
“I hold my breath and then 
take it (medicine).” (P020, 
age 50, male).  
“I closed my eyes and drink 
it and drink a lot of water.” 
(P022, age 35, female). 
“I always pray, like the 
Signa, so far it went 
smoothly. I always take the 
medicine with water, 
swallow it and pray, that is 
all I am doing.” (P029, age 














PART 5: Barriers to 
Medication Adherence and 
Barrier Management: Please 
tell me if you have 
experienced this situation and 
if so, what you did about it. 
Have you had trouble 
swallowing your medication 
and how does it taste? What 
do you do about it? 
They taste terrible, you 
have to drink more water 








Section: PART 7: Electronic 
Pillbox  
“You could take the 
container out. [It is] easy to 










Section: PART 7: Electronic 
Pillbox  
“I had 2 liquids, you can’t 
put it in the box, but you 
have to be aware that you 








Consolidated Criteria for Reporting Qualitative Research  
(COREQ) Checklist 
 
1. Interviewer/ facilitator: Which author/s conducted the interview or focus group? 
The authors, including YS, SC and the principal investigator (GS), and six other research 
assistants in the team conducted the interviews.  
 
2. Credentials: What were the researcher's credentials? E.g. PhD, MD 
The principal investigator holds a Ph.D. in psychology. Two authors (YS and SC) and six 
other research assistants were all female with either a bachelor’s or master’s degree in 
social sciences, public health or health sciences at the time of the study.  
 
3. Occupation: What was their occupation at the time of the study? 
The principal investigator was working as a research scientist at Columbia University, 
and the other members in the research team were either graduate students or recent 
graduates preparing for graduate schools.   
 
4. Gender: Was the researcher male or female? 
The interviewers were all female. 
 
5. Experience and training: What experience or training did the researcher have? 
The principal investigator is an expert in health psychology and has conducted several 
studies of frequent health behaviors with people living with and without chronic 
conditions. Interviewers were trained by the principal investigator with the interview 
guide and using role-play within the research team. Then interviewers shadowed 
interviews prior to conducting interviews with participants in the study. 
 
6. Relationship established: Was a relationship established prior to study commencement? 
There was no relationship between interviewers and participants prior to the study. 
Rather, relationships were built over the course of the study, beginning with recruitment 
and consenting by clinical staff, continuing with handing out the pillbox before or shortly 
after transplant in a research meeting before discharge home, and weekly contact after 
hospital discharge between research team and participants. By the time the interviews 
were conducted at 3 and 6 months after the first hospital discharge, participants had 
gotten to know the research team members well. Some participants sent us pictures of 
their table full of medications and also contacted the research team on their own via email 
and study phone with questions and for study logistics.  
 




Participants knew that all research team members were staff or students at Columbia 
University or Mount Sinai. Participants were aware that the research team included 
Spanish and also Mandarin speakers. Participants were also made aware that everything 
they shared with research team members would be kept confidential and would not affect 
their treatment.  
 
8. Interviewer characteristics: What characteristics were reported about the interviewer/ 
facilitator? 
The interviewers were an ethnically diverse group, with a nuanced understanding of 
different cultures. They were also fully aware of and trained in the ethics of conducting 
research, including maintaining strict confidentiality. Throughout the study, the 
interviewers tried not to be biased or look for specific results. Usually two interviewers 
conducted the interviews, with one interviewer mainly conducting the interview and the 
other audio recording and taking notes and helping to add probing questions and to keep 
the flow of the interview.  
 
9. Methodological orientation and theory: What methodological orientation was stated to 
underpin the study? (e.g. grounded theory, discourse analysis, ethnography, 
phenomenology, content analysis) 
Content analysis, more specifically directed content analysis, was utilized (Hsieh & 
Shannon, 2005). 
 
10. Sampling: How were participants selected? 
We used nonprobability sampling and participants were recruited from all patients 
undergoing alloHCT at a single urban treatment center from 08/15/2012 to 07/15/2014 
due to the nature of the specific research objective (multiple medication adherence) and 
the particular characteristics of the population (leukemia and lymphoma patients after 
alloHCT).   
 
11. Method of approach: How were participants approached? 
Clinical staff members informed patients scheduled for alloHCT of the study, either 
during pre-transplant outpatient visits prior to admission for transplant or shortly after the 
transplant and obtained informed consent from interested eligible patients. 
 
12. Sample size: How many participants were in the study? 
In total, 28 individuals (46.4% female, age: M = 53.97) participated. The sample was 
ethnically diverse, with almost half of the participants coming from a minority 
background (n = 13, 46.4%), (Non-Hispanic White: 53.6%, African American: 7.1%, 
Asian: 17.9%, Hispanic: 17.9%, other: 3.6%). Two individuals answered some of the 
interview questions but not all: Patients 20 and 21 could not complete the section on 
healthcare providers due to time constraints and health conditions. Most of the interviews 
were conducted in English (n = 26, 92.9%), some in Spanish (n = 2, 7.1%), and none in 
Mandarin because some Chinese-American participants preferred English as their 
interview language. 
 
13. Non-participation: How many people refused to participate or dropped out? Reasons? 
184 
	
Interviews from five patients were missing: Three patients were deceased, one patient 
was unavailable, and the other was too ill to participate in the interview.  
 
14. Setting of data collection: Where was the data collected? 
The study was conducted at a urban hospital. This hospital’s department of hematology 
and medical oncology has a long history of treating hematological malignancies and 
cancer. The location of the study site allowed diverse individuals to receive treatment. 
Interviews were conducted face-to-face in the hospital while participants were waiting for 
their clinical appointments or through phone interview depending on participant 
preferences. 
 
15. Presence of non-participants: Was anyone else present besides the participants and 
researchers? 
In some interviews, the caregivers were present with the participant as they accompanied 
the participants for hospital appointments. 
 
16. Description of sample: What are the important characteristics of the sample?  
Eligible participants were adults with leukemia or lymphoma cancers who had received 
an alloHCT at the hospital. Participants were eligible for the study if they were 18 years 
or older and spoke and read English, Spanish or Mandarin. 
 
17. Interview guide: Were questions, prompts, guides provided by the authors? Was it 
pilot tested? 
A theory-driven interview guide (see Appendix A) was developed by the principal 
investigator, who is an expert in health psychology and has conducted many studies in 
this area. The interview covered various topics centered around adherence and home care, 
including questions on general medication adherence, knowledge of medications, skills, 
social motivation and adherence strategies, including use of an electronic pillbox. 
Interviewers were trained by the principal investigator; the interview questions were pilot 
tested within the research team meetings and also during role-play interviews prior to 
conducting actual interviews with patients, and interviewers were also allowed to shadow 
interviews before the interviewers conducted interviews themselves.   
 
18. Repeat interviews: Were repeat interviews carried out? If yes, how many? 
The research team conducted repeat interviews with 13 participants at 3 and 6 months 
after first hospital discharge, and single interviews for 15 participants, with 10 of these 
being interviewed at 3 months and 5 at 6 months after hospital discharge. 
 
19. Audio/ visual recording: Did the research use audio or visual recording to collect the 
data? 
All interviews were audio recorded. 
 
20. Field notes: Were field notes made during and/or after the interview or focus group? 





21. Duration: What was the duration of the interviews or focus group?  
The interview lasted about 40 to 60 minutes. 
 
22. Data saturation: Was data saturation discussed? 
The research team discussed data saturation and decided to continue recruitment up to 30 
patients to obtain enough data to reflect the multifaceted experiences in this diverse 
patient population. 
 
23. Transcripts returned: Were transcripts returned to participants for comment and /or 
correction? 
No, interviews were transcribed and given to the interviewers who had conducted the 
interviews for comment and correction, but not to participants.  
 
24. Number of data coders: How many data coders coded the data? 
Two individuals coded the data (YS and SC).  
 
25. Description of the coding tree: Did authors provide a description of the coding tree? 
A codebook, based on the relevant theoretical frameworks, including the Information-
Motivation-Behavioral Skills model and classical social support theory, was developed 
under the supervision of the principal investigator. The researchers used both theory-
driven and data-driven coding. For paper 1, it was mostly data-driven coding as the 
researchers extracted relevant quotes on pillbox use, then later identified and categorized 
the quotes in different themes. For paper 2 and 3 researchers started out with theory-
driven coding, but we also applied data-driven coding along the way and identified 
additional emerging themes. Codes were modified and added as the researchers were 
reading through the transcripts. Over informed discussions between research assistants 
and the principal investigator, we refined the codebook with themes, definitions and 
examples (see Appendix B).  
 
26. Derivation of themes: Were themes identified in advance of derivation from the data? 
Yes, themes were identified based on the theoretical framework, but researchers also 
found some additional emerging themes from the interview that were not identified in the 
original theoretical model.  
 
27. Software: what software, if applicable, was used to manage the data? 
The coders (YS and SC) initially used Excel spreadsheet, and transferred all data into 
NVivo version 11 later to store, search and code the interviews in a more systematic way.  
 
28. Participant checking reporting: did participants provide feedback on the findings? 
No.  
 
29. Quotations presented: Were participant quotations presented to illustrate the 
themes/findings? Was each quotation identified? 
Yes, participant quotations were included throughout the manuscript with participant 




30. Data and findings consistent: Was there consistency between the data presented and 
the findings? 
Several authors checked that the findings presented reflected the data with the intent to 
avoid drawing any unwarranted conclusions that are not supported by the data. Intercoder 
reliability scores are provided throughout the manuscript.  
 
31. Clarity of major themes: Were major themes clearly presented in the findings? 
The findings in the manuscript are reported based on the major themes from the data. 
 
32. Clarity of minor themes: Is there a description of diverse cases or discussion of minor 
themes? 
No.  
 
